5-methoxy-n, n-dimethyltryptamine for treatment of mental motor retardation

By using 5-MeO-DMT or its salt, by interrupting and resetting the functional connection of the resting state network, the problem of insufficient efficiency and safety of psychomotor delay treatment in the prior art was solved, significantly improving the clinical response rate and Patient compliance, especially in the treatment of mental disorders and sleep disorders, has achieved significant improvements.

CN118946353APending Publication Date: 2024-11-12GH RES IRELAND LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030912.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-01-30
Filing Date
2023-03-27
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat psychomotor retardation, especially those associated with mental or neurological disorders, and previous therapies have insufficient safety, tolerance and patient compliance.

Method used

Improved dosing regimens are provided to enhance the use of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof by inhalation, nasal or sublingual administration. Efficacy and safety, and improve psychomotor retardation by interrupting and resetting functional connectivity of the resting state network.

Benefits of technology

Significantly improves the clinical response rate and durability of the patients, improves the safety and tolerance of the treatment, and enhances the patient's compliance, especially in the treatment of psychomotor retardation associated with mental disorders and sleep disorders. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005062313730001041
    Figure BDA0005062313730001041
  • Figure BDA0005062313730001061
    Figure BDA0005062313730001061
  • Figure BDA0005062313730001062
    Figure BDA0005062313730001062
Patent Text Reader

Abstract

The present invention relates to 5-methoxyl-N, N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of patients suffering from mental retardation of movement.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to improved methods for treating psychomotor retardation in patients suffering from psychiatric or neurological disorders, such as disorders characterized by depressive episodes, for example, major depressive disorder (MDD); bipolar disorder (BD), such as bipolar disorder type I and bipolar disorder type II; postpartum depression (PPD); seasonal affective disorder and persistent depressive disorder; mental and behavioral disorders due to the use of psychoactive substances, such as substance use disorder (SUD); psychotic disorders, such as schizophrenia; dementia, such as Alzheimer's disease dementia (AD); dementia with Lewy bodies (DLB); vascular dementia and Parkinson's disease dementia; Parkinson's disease; chronic fatigue syndrome.

[0002] Patients with sleep disorders such as insomnia may also experience psychomotor retardation.

[0003] The treatment comprises administering to a patient in need thereof a therapeutically effective amount of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof. Background Art

[0004] Psychomotor retardation is characterized by decreased energy and activity and decreased motivation. Psychomotor retardation involves slower thinking and decreased physical movement in an individual. Impaired psychomotor function may result in noticeably slower physical and emotional responses.

[0005] Therefore, there is a need for improved methods of treating psychomotor retardation, particularly psychomotor retardation associated with psychiatric or neurological disorders. Summary of the invention

[0006] It is an object of the present invention in particular to provide improved therapies that are more effective than previously described therapies (i.e., a) a greater percentage of patients experience a clinical response, b) a greater mean clinical response, c) an earlier onset of clinical response, and / or d) a more durable clinical response).

[0007] It is a further object of the present invention to provide compounds for improved psychoactive therapy and dosing regimens for said therapy, said therapy having better safety and / or better tolerability than previously described therapies. It is another object of the present invention to provide compounds for improved psychoactive therapy and dosing regimens for said therapy, said therapy being more convenient than previously described therapies. It is another object of the present invention to provide compounds for improved psychoactive therapy and dosing regimens for said therapy, said therapy being associated with higher patient compliance rates (including higher treatment initiation rates) than previously described therapies. It is a still further object of the present invention to identify specific disease aspects and subgroups of specific disease aspects that may benefit from such improved psychoactive therapies.

[0008] The present invention provides 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for treating patients suffering from psychomotor retardation.

[0009] The present invention provides improved methods for treating psychomotor retardation, particularly psychomotor retardation in patients suffering from psychiatric or neurological disorders, such as disorders characterized by depressive episodes, for example, major depressive disorder (MDD); bipolar disorder (BD), such as bipolar disorder type I and bipolar disorder type II; postpartum depression (PPD); seasonal affective disorder and persistent depressive disorder; mental and behavioral disorders due to the use of psychoactive substances, such as substance use disorder (SUD); psychotic disorders, such as schizophrenia; dementia, such as Alzheimer's disease dementia (AD); dementia with Lewy bodies (DLB); vascular dementia and Parkinson's disease dementia; Parkinson's disease; chronic fatigue syndrome.

[0010] The present invention also provides improved methods for treating psychomotor retardation in patients suffering from sleep disorders (eg, insomnia).

[0011] The present invention also provides dosage ranges and administration regimens useful for treating psychomotor retardation. DETAILED DESCRIPTION

[0012] definition

[0013] As used in the context of the present invention, unless otherwise indicated, the term "5-MeO-DMT" refers to the free base 5-MeO-DMT. It is contemplated that pharmaceutically acceptable salts of 5-MeO-DMT may also be used. Such salts are particularly acid addition salts, wherein the acid may be selected from, for example, acetic acid, benzoic acid, citric acid, fumaric acid, hydrobromic acid, hydrochloric acid, hydrofluoric acid, hydroiodic acid, oxalic acid, succinic acid and trifluoromethanesulfonic acid. A preferred example is the hydrobromide salt. The appropriate weight of the salt to be administered may be calculated based on the weight of the free base, assuming the use of equimolar amounts.

[0014] As used in the context of the present invention, a "patient" to be treated is a human subject who has been diagnosed by a licensed professional in accordance with generally accepted medical practice as suffering from psychomotor retardation or who has been diagnosed by a licensed professional in accordance with generally accepted medical practice as suffering from a psychiatric disorder or a neurological disorder associated with psychomotor retardation. In the latter case, assessment of psychomotor retardation may or may not be part of the diagnosis.

[0015] For example, the diagnosis of mental disorder or nervous system disorder can be carried out according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) issued by the American Psychiatric Association. In some cases, as will be apparent from the discussion of the specific circumstances below, it is possible to modify or supplement standards to better define a patient or patient population that is particularly benefited from treatment according to the present invention. In any case, diagnosis will be carried out by a doctor or psychologist. It is not enough for a human subject to believe that he suffers from the disorder.

[0016] As used in the context of the present invention, unless otherwise indicated, the terms "treating" and "treatment" shall include the management and care of a patient for the purpose of combating a disease, illness or disorder, and includes the administration of the compounds and methods according to the present invention to alleviate the signs and / or symptoms of the disease or to eliminate the disease, illness or disorder.

[0017] "Treatment of psychomotor retardation" shall include the management and care of a patient for the purpose of combating psychomotor retardation and includes the administration of the compounds and methods according to the present invention to alleviate the signs and / or symptoms of psychomotor retardation or to eliminate psychomotor retardation.

[0018] Psychomotor retardation may be associated with a sleep disorder (such as insomnia), a psychiatric or neurological disorder, or other medical conditions.

[0019] The patient may suffer from a treatment-resistant disease. Treatment resistance means that the patient has not adequately improved after at least two adequate courses of treatment. The patient has not adequately improved after at least two adequate courses of treatment, in particular, at least one of the two courses is drug therapy; for example, the patient has not adequately improved after at least two adequate courses of drug therapy. In particular, at least two prior courses of treatment were administered during the current episode of the disease, for example, if the patient suffers from a disorder characterized by a depressive episode, during the current depressive episode.

[0020] As used in the context of the present invention, and unless otherwise indicated, the term "therapeutically effective amount" shall mean that amount of an active compound or pharmaceutical ingredient that elicits the biological or clinical response in a human being that is being sought by a researcher, physician or other clinician, including alleviation of the signs and / or symptoms of the disease, condition or disorder being treated.

[0021] "Clinical response" includes, but is not limited to, improvement on rating scales that assess (i) psychomotor retardation or aspects of psychomotor retardation and / or (ii) a psychiatric or neurological disorder or aspects of such a disorder and / or (iii) sleep.

[0022] The severity of the disorder, as well as changes in severity, can be assessed by the Clinical Global Impression (CGI) rating scale, which is a measure of symptom severity, treatment response, and efficacy of treatment.

[0023] The CGI rating scale was developed to provide a brief, independent assessment of the clinician's perception of a patient's global functioning before and after treatment (Busner, J. and Tagrum, SD, 2007. The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice. Psychiatry 2007, 29-37).

[0024] The CGI severity (CGI-S) is based on a single question that clinicians must answer: “Given your overall clinical experience with this particular population, how ill is the patient currently?” Rated on a seven-point scale: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = somewhat severely ill; 6 = severely ill; and 7 = the sickest patient.

[0025] The CGI-S can be used to assess treatment success by comparing scores before and after treatment.

[0026] The clinical response may be reflected by a reduction in the Clinical Global Impression-Severity (CGI-S) score. According to the present invention, a reduction in the CGI-S score means that the CGI-S is reduced by at least 1 point. Preferably, the CGI-S is reduced by at least 2 points and / or to 0 points. Particularly preferably, the CGI-S is reduced by at least 3 points and / or to 0 points.

[0027] Alternatively, treatment success can be assessed using the CGI-Improvement (CGI-I), which has an equally simple format. After treatment, the clinician compares the patient's overall clinical condition with the condition before treatment (the so-called baseline value). Again, there is only one inquiry rated on a seven-point scale: "Compared with the patient's condition at admission (before starting medication), is this patient's condition: 1 = very much improved since starting treatment; 2 = much improved; 3 = slightly improved; 4 = no change from baseline (start of treatment); 5 = slightly worse; 6 = a lot worse; 7 = very much worse since starting treatment."

[0028] The Patient Global Impression (PGI), also known as the Subject Global Impression (SGI), is the counterpart of the Clinical Global Impression (CGI). It consists of one item based on the CGI and adapted for the patient. It can measure disease severity (PGI-S) or disease improvement (PGI-I).

[0029] Individual items as well as subcombinations of individual items of the scales as described herein can be used to assess specific disease aspects.

[0030] As used in the context of the present invention, unless otherwise indicated, the term "administering" (or "application") shall mean introducing an amount (which may be a predetermined amount) of an active compound or pharmaceutical ingredient into a patient's body via any route. Preferably, the active compound is administered by inhalation, nasal, buccal or sublingual administration.

[0031] As used in the context of the present invention, unless otherwise indicated, the terms "dose" and "dosage" and "dosage amount" shall mean the amount of active compound or pharmaceutical ingredient administered to a patient in a single administration. The term "dosage regimen" (or "dosage regimen") shall mean a defined order of one or more separate administrations.

[0032] As used herein, "aerosol" means a stable system consisting of a gaseous medium (a pharmaceutically acceptable gas, such as air) and tiny suspended solid and / or liquid particles. The term "degradation product" refers to a compound produced by the chemical modification of 5-MeO-DMT due to a chemical reaction during the formation of the aerosol. Such reactions include, but are not limited to, oxidation. When describing the percentage of "degradation product" in the context of the present invention, this refers to the amount of 5-MeO-DMT degradation products present in the sample divided by the amount of 5-MeO-DMT plus 5-MeO-DMT degradation products present in the sample multiplied by 100%, that is, (the sum of the amounts of all 5-MeO-DMT degradation products present in the sample) / ((the amount of 5-MeO-DMT present in the sample)+(the sum of the amounts of all 5-MeO-DMT degradation products present in the sample)) x 100%. As used herein, the term "impurity" refers to an unwanted compound that contaminates a sample of 5-MeO-DMT (or a pharmaceutically acceptable salt thereof). Impurities may be included in the starting materials prior to aerosol formation or may be degradation products.

[0033] The term "purity" refers to 100% minus the percentage of all 5-MeO-DMT degradation products present and all other impurities present, i.e., 100% - (the sum of the amounts of all 5-MeO-DMT degradation products present + the sum of the amounts of all other impurities present) / (the amount of 5-MeO-DMT present + the sum of the amounts of all 5-MeO-DMT degradation products present + the sum of the amounts of all other impurities present) x 100%.

[0034] The term "mass median aerodynamic diameter" (MMAD) is the diameter at which 50% of the particles present in the aerosol are larger than the calculated diameter and 50% of the particles are smaller than the calculated diameter. The term "aerosol particle mass density" refers to the mass of aerosol particles per unit volume of aerosol. The term "aerosol particle formation rate" refers to the mass of 5-MeO-DMT aerosolized per unit aerosolization time.

[0035] Psychomotor retardation

[0036] The key aspects observed in patients suffering from psychomotor retardation are decreased energy and activity and decreased motivation.

[0037] Psychomotor retardation involves a person's slower thinking and decreased physical movement. Impaired psychomotor function may result in noticeably slower physical and emotional responses.

[0038] Psychomotor retardation may be associated with a psychiatric or neurological disorder or some other medical condition.

[0039] Mental or neurological disorders that cause or are associated with psychomotor retardation include disorders characterized by depressive episodes, such as major depressive disorder (MDD); bipolar disorder (BD), such as bipolar disorder type I and bipolar disorder type II; postpartum depression (PPD); seasonal affective disorder and persistent depressive disorder; mental and behavioral disorders due to the use of psychoactive substances, such as substance use disorder (SUD); psychotic disorders, such as schizophrenia; dementia, such as Alzheimer's disease dementia (AD); dementia with Lewy bodies (DLB); vascular dementia and Parkinson's disease dementia; Parkinson's disease; chronic fatigue syndrome.

[0040] Patients with sleep disorders such as insomnia may also experience psychomotor retardation.

[0041] Measuring psychomotor retardation

[0042] Psychomotor retardation can be assessed by measuring various aspects. These can include, for example, various types of drawing tasks and tests, such as the Trail Making Test (TMT), the Digit Symbol Substitution Test (DSST), or the Gibson Spiral Maze Test (GSM), as well as other tests known in the art.

[0043] For example, in the Tracking and Making Test (TMT), the subject must connect 25 circles containing numbers (TMT A) or numbers and letters (TMT B) in ascending order. The task requirements of TMT-B are similar, except that the subject must alternate between numbers and letters (1, A, 2, B, 3, C, etc.). Therefore, the test evaluates processing speed (TMT A) or cognitive flexibility (TMT B). The scoring of each part represents the time required to complete the task.

[0044] Another test involving written motor skills is the Gibson spiral maze (GSM), which assesses only psychomotor speed and is not influenced by cognitive ability. To complete the GSM, subjects must correctly trace a spiral maze from the start to the end without touching the border lines.

[0045] The Digit Symbol Substitution Test (DSST) also measures psychomotor speed and consists of digit-symbol pairs and lists of numbers. Under each number, the subject should write down the corresponding symbol as quickly as possible. The score is determined by the number of symbols reported correctly within 90 seconds. Another example of a motor test is the finger tapping test.

[0046] Therefore, some tests combine measures of both motor and cognitive aspects of psychomotor retardation, whereas other tests assess only the motor aspects.

[0047] Speech analysis can serve as a further indicator of psychomotor retardation.

[0048] The main scales that can be used for assessment and measurement include the severity of psychomotor retardation, the Salpêtrière Slowness Rating Scale (SRRS), and the Motor Agitation and Retardation Scale (MARS).

[0049] The Salpêtrière Slowness Rating Scale (SRRS) was developed to assess cognitive and motor aspects through fifteen items. The first three indicators measure the quality of movement, especially stride length and the slowness of limb, trunk, head and neck movements. The next three items focus on speech and include speech fluency, intonation and length of answers. Two items were designed to measure cognitive function objectively. These questions are based on interview dialogues and measure the patient's ability to approach and expand on topics. Further items are subjective and assess brooding, fatigue, interest level, time perception, memory and attention. The last item of the scale is related to the overall assessment of the patient's psychomotor slowness. Based on the severity of the symptoms presented, the item scores range from 0 (no symptoms) to 4 (severe), and the total score ranges from 0 to 60.

[0050] The Motor Agitation and Retardation Scale (MARS) assesses motor aspects only. It is designed to assess psychomotor disturbances in depressive disorders. Psychomotor disturbances are divided into five major physical categories: eyes, face, voice, limbs, and trunk, with a total of 19 items on the scale. Items in the eyes category include gaze direction, number of blinks, gaze, and eye movements. Items related to the face category include facial expression and facial expressivity. The voice category has items including volume, slurring, pitch, and onset time. Items under the limb category include movements of the hands, feet, and legs, stride length, slowness of movements, and tension in the hands. Items under the trunk category include posture, immobility, and axial movements. The severity of each item ranges from 1 to 4, with 4 being the most severe. Of the 19 items, 9 are related to motor agitation, and 10 items assess motor retardation. The MARS scale allows for a rapid clinical assessment of motor signs.

[0051] Scales for the assessment of mental and neurological disorders

[0052] A variety of scales have been proposed to assess the severity of psychiatric or neurological disorders. Such scales are based on tests that can be self-administered or administered by a clinician.

[0053] Scales that can be used in accordance with the present invention include those known in the art for diagnosing and / or monitoring psychiatric or neurological disorders as discussed in more detail below.

[0054] Treatment outcomes are assessed by using one or more indices or scales at one or more time points after completion of the course of treatment.

[0055] The assessment can be performed after the acute psychedelic experience has subsided. An appropriate time point for early assessment is generally about 2 to 3 hours after the last administration. Early assessment can generally be performed, for example, about 2 hours or about 3 hours after the last administration.

[0056] However, assessment of the effects on sleep disturbance can be performed as early as the day after treatment (ie, day 1), allowing treated patients the opportunity to get at least one night of sleep.

[0057] Thus, an assessment on day 1 or day 1 means an assessment on the second day after administration. The assessment will be performed no earlier than 12 hours after the last administration, and in any case no earlier than one night after the last administration, and no later than 36 hours after the last administration. The assessment may be performed after about 24 hours.

[0058] Assessment on or at day 7 means assessment performed on the seventh day after administration (the day of administration is day 0). Similar definitions apply to other assessment times measured in days.

[0059] When clinical response is assessed at an early time point (e.g., 2 hours) after drug administration, for example, when one of the scales is used to assess the severity of a psychiatric or neurological disorder, such endpoints may be reasonably modified based on endpoints developed for longer recall periods (e.g., MADRS is typically 7 days) (e.g., changing the MADRS recall period to 2 hours and carrying forward sleep items recorded at baseline before drug administration). This also applies to any other scale used herein, unless a recall period is specifically specified.

[0060] The considerations outlined apply to early time points because, on the one hand, in order to assess clinical response, the influence of the patient's pre-treatment status on any scores recorded after treatment should be as low as possible, while on the other hand, sleep items cannot be assessed 2 hours after drug administration.

[0061] At a later time point, such as on day 1 or later, all items of the relevant scales used to assess clinical response can generally be assessed, using an appropriate recall period (if necessary), so that no pre-treatment scores need to be carried forward.

[0062] Resting-state networking and psychomotor retardation

[0063] Brain processes can be studied by functional magnetic resonance imaging (fMRI). Brain activity is correlated with blood flow, and the temporal correlation of spontaneous blood oxygen level-dependent (BOLD) signal fluctuations between different brain regions can be measured.

[0064] Functional images of the brain are acquired over several minutes. Low-frequency BOLD signal oscillation patterns are observed throughout the brain. Decomposition of this spontaneous signal reveals distributed regions with correlated and inversely correlated fluctuations.

[0065] In this way, resting-state fMRI can be used to characterize large-scale functional networks, so-called resting-state networks (RSNs), which are a set of spatially distinct brain regions that exhibit coordinated activity in the absence of any explicit cognitive task (i.e., at rest). The observed patterns characterize a network of brain regions with coherent patterns of signal changes, which are called resting-state networks (RSNs).

[0066] Different resting-state networks have been identified and named, primarily based on spatial similarities between resting-state networks and activation patterns observed in task-related fMRI experiments.

[0067] Therefore, resting-state fMRI can be used to assess the intrinsic functional organization of the brain. Resting-state networks are characterized by aspects of attention, memory, cognitive control, default mode, motor, and sensory systems.

[0068] RSNs have been shown to be responsible for various aspects of complex brain function, and these networks of connections have been found to be impaired in a variety of disease states. Such disease states, including certain forms of psychomotor retardation, are associated with altered functional connectivity within specific resting-state networks and / or between one or more regions in one or more additional resting-state networks.

[0069] For example, abnormal functional connectivity from the somatosensory motor network (SMN) to the visual (VN), dorsal attention (DAN), and default mode networks has been reported to be associated with psychomotor retardation and agitation in depressive disorders.

[0070] In many cases, the resting-state network involved in psychomotor retardation is affected by psychiatric or neurological disorders characterized by depressive episodes, such as major depressive disorder (MDD); bipolar disorder (BD), such as bipolar disorder type I and bipolar disorder type II; postpartum depression (PPD); seasonal affective disorder and persistent depressive disorder; mental and behavioral disorders due to the use of psychoactive substances, such as substance use disorders (SUD); psychotic disorders, such as schizophrenia; dementia, such as Alzheimer's disease dementia (AD); dementia with Lewy bodies (DLB); vascular dementia and Parkinson's disease dementia; Parkinson's disease; chronic fatigue syndrome.

[0071] The resting-state network involved in psychomotor retardation is also affected by sleep disturbances such as insomnia. In fact, psychomotor retardation and impaired sleep are correlated.

[0072] Treatment of psychomotor retardation and mental or nervous system disorders

[0073] According to the present invention, psychomotor retardation in patients suffering from mental disorders or nervous system disorders can be treated. In addition, psychomotor retardation in patients suffering from sleep disorders (such as insomnia) can be treated.

[0074] For patients suffering from psychomotor retardation associated with another disorder detailed above, treatment of the psychomotor retardation according to the invention may improve the disorder associated with the psychomotor retardation.

[0075] Treatment according to the present invention is by administering 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0076] Administration of 5-MeO-DMT to patients disrupts established functional connectivity patterns within and / or between resting-state networks. This disruption results in the resetting of pathological, poorly connected connections as the networks rewire. New, healthy functional connections are established, and this has lasting effects.

[0077] Therefore, according to the present invention, affecting these resting state networks through therapies as described herein will lead to improvement in psychomotor retardation, and if the patient being treated suffers from a psychiatric disorder or a neurological disorder, the disorder will also be improved; if the patient being treated suffers from a sleep disorder, such as insomnia, the sleep disorder (such as insomnia) will also be improved.

[0078] To further support the clinical utility of 5-MeO-DMT in patients suffering from psychomotor retardation, the inventors evaluated clinical data associated with the use of 5-MeO-DMT in patients being treated for psychiatric disorders and noted particular improvements in psychomotor retardation, which is also commonly observed in patients suffering from other disorders.

[0079] The data are from a recently completed clinical trial investigating the use of 5-MeO-DMT to treat patients diagnosed with treatment-resistant depression (TRD; see also the Examples section below). Although TRD is a specific disorder, as discussed in detail below, the inventors determined that certain clinical observations made in the trial are relevant to the design of treatments for other disorders associated with psychomotor retardation.

[0080] In clinical trials, 5-MeO-DMT was administered via inhalation (as described in more detail in the Examples section below). Patients were assigned to different groups. Of interest in the context of the present invention are the group that received a single 12 mg dose, and the group that received an intra-day individualized dosing regimen (IDR) that allowed multiple dose increases (6 mg, 12 mg, and 18 mg) throughout the day, depending on the intensity of the psychedelic experience reported by the patient.

[0081] The data collected included assessments of the treated patients on several scales, including the Montgomery-Asberg Depression Rating Scale (MADRS). Although the focus of the trial was to demonstrate treatment efficacy through improvements in the overall MADRS score, the inventors focused on the items that make up the various rating scales and noticed that specific sub-score items (such as those related to psychomotor retardation) were associated with other disorders in which psychomotor retardation was based on similarly altered functional connectivity within and / or between the somatomotor / sensorimotor, visual, dorsal attention, and default mode networks.

[0082] Multiple patients in the recruited cohort showed significant improvements, and this result confirms the inventors' findings that 5-MeO-DMT is a suitable compound for the treatment of patients experiencing these symptoms.

[0083] More specifically, one aspect that can be treated by administering 5-MeO-DMT is psychomotor retardation. 5-MeO-DMT can be administered to a patient to reduce or eliminate psychomotor retardation in the patient.

[0084] The item in the MADRS scale that is particularly relevant to psychomotor retardation is “slouching,” which indicates difficulty starting or slowness in initiating and performing daily activities.

[0085] A score of 0 means almost no difficulty in getting started and no slowness. If the patient has trouble starting an activity, the score is 2. A score of 4 means difficulty starting simple daily activities that require effort. If the patient is completely lazy and cannot do anything without help, the score is 6.

[0086] In the study group that received the individualized dosing regimen, the total score for the MADRS item “laziness” was 27 at baseline for all eight patients.

[0087] After 2 hours, the score dropped to 10, which corresponds to 17 points or 63% improvement. On the first day after treatment, the score dropped to 5, which corresponds to 22 points or 81% improvement. On the seventh day after treatment, the score dropped to 3, which corresponds to 24 points or 89% improvement.

[0088] In the 12 mg group, the total score of the MADRS item "slouching" for all 4 patients was 16 at baseline. After 2 hours, the score dropped to 10, which corresponds to an improvement of 6 points or 38%. On the first day after treatment, the score dropped to 0, which corresponds to an improvement of 16 points or 100%. On the seventh day after treatment, the score dropped to 3, which corresponds to an improvement of 13 points or 81%.

[0089] Thus, the score of the scale item "slothiness", which is particularly relevant to psychomotor retardation, was significantly improved. The inventors concluded that 5-MeO-DMT can be used to treat psychomotor retardation in patients, especially those who also suffer from psychiatric or neurological disorders or sleep disorders (e.g. insomnia).

[0090] Thus, according to the present invention, treatment of a patient suffering from psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation.

[0091] Active Agent

[0092] The above discussion shows that psychomotor retardation itself carries a significant disease burden and requires appropriate treatment.

[0093] The inventors believe that carefully selected hallucinogens may lead to treatments that improve important aspects of psychomotor retardation, and may lead to overall improvement of the disorder.

[0094] A group of hallucinogens consists of compounds that bind to 5-hydroxytryptamine (5-HT) receptors, also known as serotonin receptors (seven families with several subtypes are described, 5-HT1 to 5-HT7). Examples are lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT). These serotonergic agents are often called "psychedelics", which emphasizes their primary ability to induce qualitative changes in states of consciousness, such as euphoria, trance, time and space, spiritual experiences, loss of self-boundaries, or even near-death experiences, while other effects, such as sedation, anesthesia, or overstimulation, are minimal.

[0095] Chemically, serotonergic psychedelics are either phenylalkylamines or indoleamines, with the indoleamines divided into two subsets, the ergoline and the tryptamines, the latter of which are derived from tryptamine.

[0096] Various serotonergic psychedelics have different binding affinities and activation potencies for various serotonin receptors (particularly 5-HT1A, 5-HT2A, and 5-HT2C), and their activities may also be modulated through interactions with other targets such as monoamine transporters and trace amine-associated receptors.

[0097] Recently published studies using serotonergic psychedelics such as LSD, psilocybin, and DMT (using the shamanic medicine ayahuasca containing DMT) in certain psychiatric disorders suggest that these compounds may offer an alternative approach to currently available treatments for some psychiatric disorders. However, there are reports that these compounds may induce mania in patients suffering from depressive symptoms, and this may hamper their clinical use.

[0098] For example, Lake et al. (Lake, CR, Stirba, AL, Kinneman, REJr, Carlson, B., Holloway, HC, 1981. Mania associated with LSD ingestion. American Journal of Psychiatry. 138 (11): 1508-9) reported a patient who had a manic episode after taking LSD or LSD analogs. The patient had symptoms of acute LSD intoxication, which were relieved, but a typical psychotic manic episode occurred about 3 weeks later. Hendin and Penn (Hendin, HM, Penn, AD, 2021. An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report. Bipolar Disorders 23 (4): 1-3) reported a manic episode after self-reported ingestion of psilocybin mushrooms. Szmulewicz et al. (Szmulewicz, AG, Valerio, MP and Jose MSmith, JM, 2015. Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report. International Journal of Bipolar Disorders (2015) 3:4) reported a man with bipolar disorder who switched to mania after consuming ayahuasca, a beverage containing DMT.

[0099] Another case report can be found in Brown, T., Shao, W., Ayub, S., Chong, D., & Cornelius, C. (2017). A Physician's attempt to self-medicate bipolar depression with N, N-dimethyltryptamine (DMT). Journal of Psychoactive Drugs, 49 (4), 294-296.

[0100] The inventors believe that in order to avoid inducing mania or hypomania, or at least reduce the risk of inducing mania or hypomania, the administered compound must be appropriately selected and preferably administered according to a specific dosing regimen.

[0101] The inventors have identified 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) as a psychedelic of particular interest for use in therapy. 5-MeO-DMT has unique pharmacological properties that are distinct from other psychedelic compounds.

[0102] 5-MeO-DMT is a potent, fast-acting, naturally occurring serotonin (5-HT) agonist that acts at both 5-HT1A and 5-HT2A receptors, with a higher affinity for the 5-HT1A receptor subtype than other classic psychedelics.

[0103] As further detailed in the Examples section below, the inhibition constants (K) for psilocin (the dephosphorylated form of psilocybin formed following ingestion of psilocybin), DMT, and 5-MeO-DMT at the 5-HT1A receptor located in the hippocampus of postmortem human brains are shown in Table 1. i The inhibitory constants (K values) of psilocybin dephosphate, DMT, and 5-MeO-DMT at the 5-HT2A receptor in the frontal cortex of postmortem human brains were 48, 38, and 1.80 nM, respectively. Thus, 5-MeO-DMT exhibits high affinity for the 5-HT1A receptor, while dephosphopsilin and DMT exhibit moderate affinity. i values) were 37, 117, and 122 nM, respectively. Thus, dephosphorylated psilocybin exhibits moderate / strong affinity for the 5-HT2A receptor, whereas DMT and 5-MeO-DMT exhibit relatively weak affinity.

[0104] Relative to the other psychoactive compounds mentioned previously, 5-MeO-DMT exhibits an enhanced affinity for the 5-HT1A receptor, where 5-MeO-DMT acts as a potent agonist. Relative to 5-MeO-DMT, the contribution of 5-HT2A binding is increased in the case of dephosphorylated psilocybin and DMT, with 5-MeO-DMT exhibiting the greatest differential affinity for 5-HT1A relative to 5-HT2A among the three compounds. Thus, 5-HT1A binding relative to 5-HT2A binding plays a much larger role in the overall effects of 5-MeO-DMT than the other two compounds.

[0105] 5-HT1A agonists reportedly reduce impulsivity and aggression, whereas 5-HT2A agonists cause short-term increases in these same traits. Additionally, the dopamine system has been implicated in causing mania, with increases in dopamine drive being associated with mania. LSD, psilocybin, and DMT exhibit increased affinity for multiple dopamine receptors relative to 5-MeO-DMT.

[0106] Compared to other psychedelics (such as LSD, psilocybin, or DMT), 5-MeO-DMT can be preferably administered to patients using a dosing regimen as described herein without producing a significant risk of inducing mania or hypomania in patients suffering from psychiatric or neurological disorders, including disorders characterized by depressive episodes, such as major depressive disorder (MDD), postpartum depression (PPD), persistent depressive disorder, seasonal affective disorder, and bipolar disorder (BD), such as bipolar disorder type I and bipolar disorder type II; psychotic disorders, such as schizophrenia; or personality disorders, such as schizotypal personality disorder. Patients suffering from such psychiatric or neurological disorders and treated according to the present invention do not experience treatment-induced mania or hypomania.

[0107] It is also noteworthy that reports of treatment-induced mania or hypomania associated with psychoactive substance use appear to indicate use of a large number of the corresponding compounds (e.g., DMT / ayahuasca, psilocybin, LSD).

[0108] The inventors' sequential up-titration method of 5-MeO-DMT significantly reduces the risk of overdose and the likelihood of attendant adverse events.

[0109] Further, it has been reported that antidepressants induce isolated hypomanic episodes in patients suffering from treatment-resistant depression (TRD) (Bader, Cynthia D. and David L. Dunner. "Antidepressant-induced hypomania in treatment-resistant depression." Journal of Psychiatric Practice 13.4 (2007): 233-237). However, a recently completed clinical trial of 5-MeO-DMT in patients with TRD showed no evidence of inducing hypomania.

[0110] 5-MeO-DMT can induce peak experiences (i.e., experiences characterized by a shift in emotional perspective, described as a "loss of self," typically ending in an overwhelming sense of "oneness with the universe") more quickly than other psychedelics and has a shorter duration of acute psychedelic effects (5 to 30 minutes after inhalation, compared to hours with, e.g., oral psilocybin and oral LSD). These properties of 5-MeO-DMT are associated with an improved therapeutic profile, which can be explained by specific alterations in resting state network (RSN) activity under 5-MeO-DMT treatment.

[0111] In addition, 5-MeO-DMT is a 5-HT7 receptor agonist with high affinity for the receptor. The inventors used recombinant human 5-HT7 receptor, [ 3 H]LSD and serotonin to estimate nonspecific binding and determine K i It is 2.3nM.

[0112] Thus, in addition to the 5-HT1A and 5-HT2A receptors discussed above, 5-MeO-DMT also interacts with the 5-HT7 receptor. 5-MeO-DMT acts as an agonist at this receptor and exhibits high (nanomolar) binding affinity.

[0113] The 5-HT7 receptor plays a role in neurogenesis, synaptogenesis and dendritic spine formation. It is associated with central processes such as learning and memory, sleep regulation and circadian rhythms, and nociception, among others.

[0114] 5-HT7 receptors are expressed particularly in Purkinje neurons of the spinal cord, raphe nuclei, thalamus, hypothalamus (including the suprachiasmatic nucleus), hippocampus, prefrontal cortex, striatal complex, amygdala, and cerebellum.

[0115] The suprachiasmatic nucleus is the central pacemaker of the circadian timing system. It coordinates circadian rhythms in various brain regions. Disruption of this coordination leads to disease states, particularly those involving sleep disturbances. In patients with sleep disturbances, resting-state functional connectivity analysis revealed altered functional connectivity between the suprachiasmatic nucleus and regions within the default mode network.

[0116] The expression of 5-HT7 receptors in the suprachiasmatic nucleus corresponds to the role of said receptors in regulating the sleep / wake cycle. The inventors believe that this allows the treatment of patients suffering from sleep disorders by 5-MeO-DMT acting on the receptors.

[0117] The inventors believe that the combination of 5-MeO-DMT and the 5-HT7 receptor (as a mediator of the pharmacological effects of 5-MeO-DMT) involves a "resetting" of the functional connectivity of the network and a neuroplasticity effect, which contributes to the beneficial effects of 5-MeO-DMT in the treatment of patients suffering from sleep disorders.

[0118] The inventors further believe that the binding of 5-MeO-DMT to the 5-HT7 receptor and the 5-HT1A receptor (two mediators through which 5-MeO-DMT acts) involves a "resetting" of the functional connectivity of the network and neuroplasticity effects, allowing for beneficial effects in patients suffering from other symptoms or disorders such as cognitive dysfunction, anxiety, negative thinking, sleep disturbances, or social / emotional withdrawal. This is supported by the clinical results shown in the studies cited herein.

[0119] Another characteristic of 5-MeO-DMT is its short half-life.

[0120] 5-MeO-DMT is primarily inactivated through a monoamine oxidase A-mediated deamination pathway and is O-demethylated by cytochrome P450 2D6 (CYP2D6) enzymes.

[0121] The inventors studied the pharmacokinetic properties of 5-MeO-DMT and observed rapid absorption and distribution of inhaled 5-MeO-DMT, with maximum concentrations and pharmacological effects observed during and immediately after dosing.

[0122] Analysis of the pharmacokinetic properties of 5-MeO-DMT after inhalation showed that plasma concentrations decreased very rapidly. Ten minutes after administration, concentrations dropped to 10% or less of Cmax; after 2 hours, concentrations were 1% or less of Cmax; and after 3 hours, 5-MeO-DMT was no longer detected in the plasma. This applied to the entire dose range tested (6 mg, 12 mg, 18 mg). No accumulation was observed after repeated administration over a time range of 1 to 4 hours. Up-titration as disclosed herein does not result in accumulation and therefore does not result in higher plasma concentrations, for example, 10 minutes, 2 hours, or 3 hours after administration.

[0123] The properties of 5-MeO-DMT make the compound particularly suitable for treating psychomotor retardation, particularly in patients suffering from psychiatric or neurological disorders.

[0124] The properties of 5-MeO-DMT also allow for specific dosing regimens, as discussed in more detail below.

[0125] According to the present invention, isotopic variants of 5-MeO-DMT and pharmaceutically acceptable salts thereof may also be used.When referring to the use of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, the use of isotopic variants is also contemplated.

[0126] These variants are in particular deuterated forms of 5-MeO-DMT and pharmaceutically acceptable salts of such forms.

[0127] A deuterated form of 5-MeO-DMT is one that contains more deuterium than would be expected based on the natural abundance of this isotope.

[0128] The deuterated form of 5-MeO-DMT is a specific form in which deuterium is introduced at one or more defined hydrogen positions.

[0129] Examples of deuterated forms of 5-MeO-DMT include, but are not limited to, 1-deuterio-2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethylamine, 1,1-dideuterio-2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethylamine, 1,1,2,2-tetradeuterio-2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethylamine, and N,N-dimethyl-2-[5-(trideuteriomethoxy)-1H-indol-3-yl]ethylamine.

[0130] Further examples include forms of 5-MeO-DMT in which deuterium has been introduced at one or more hydrogen positions of the N-bound methyl group. Still further examples include forms of 5-MeO-DMT in which one or more deuterium atoms replace hydrogen atoms of the indole ring system. It is also worth noting that combinations of the above substitution patterns are also contemplated.

[0131] Methods for the preparation of these compounds are known in the art.

[0132] Mixtures of deuterated forms of 5-MeO-DMT, mixtures of one or more deuterated forms with non-deuterated 5-MeO-DMT, pharmaceutically acceptable salts of deuterated forms of 5-MeO-DMT, mixtures of such salts, and mixtures of salts of deuterated 5-MeO-DMT and non-deuterated 5-MeO-DMT may also be used in accordance with the present invention.

[0133] Furthermore, according to the present invention, the amount of deuterated 5-MeO-DMT and deuterated 5-MeO-DMT salts used is equimolar to the amount of the corresponding non-deuterated form.

[0134] According to the present invention, prodrugs of 5-MeO-DMT and pharmaceutically acceptable salts of such prodrugs may also be used. Such prodrugs of 5-MeO-DMT may be converted to 5-MeO-DMT by metabolism. Therefore, when referring to the use of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, the 5-MeO-DMT prodrug or a salt thereof may be used instead.

[0135] In a suitable prodrug, the hydrogen in position 1 of the indole moiety is replaced by an organic moiety which can be cleaved after administration.

[0136] An example of a suitable organic moiety is C(O)OR 1 、-C(O)R 2 、-CH(R 3 )OR 4 、-C(O)OCH(R 3 )OC(O)R 4 、-C(O)OCH(R 3 )OC(O)OR 4 、-CH(R 3 )C(O)R 4 、-CH(R 3 )OC(O)R 4 、-CH(R 3 )OC(O)OR 4 , where R 1 , R 2 , R 3 and R 4 Each of is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein each alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently substituted or unsubstituted.

[0137] A preferred example of an organic moiety is -CH(R 3 )OC(O)R 4 and -C(O)OR 1 , where R 1 , R 3 and R 4 As defined above.

[0138] Prodrugs, especially prodrugs of the above structure, can also be used in the form of pharmaceutically acceptable salts.

[0139] Specific examples of prodrugs are 5-MeO-DMT carboxyisopropyl valine ester, preferably in salt form, in particular as ditrifluoroacetate (1-(((S)-2-amino-3-methylbutanoyl)oxy)-2-methylpropyl 3-(2-(dimethylamino)ethyl)-5-methoxy-1H-indole-1-carboxylic acid ditrifluoroacetate) and 5-MeO-DMT methyl pivalate (3-(2-(dimethylamino)ethyl)-5-methoxy-1H-indol-1-yl)methyl pivalate).

[0140] Methods for preparing prodrugs as discussed herein are known in the art.

[0141] According to the present invention, the T of the metabolite 5-MeO-DMT measured after oral administration of the prodrug at 10 mg / kg in male Sprague-Dawley (SD) rats max The value is preferably 1 hour or less, more preferably 0.7 hour or less, particularly 0.5 hour or less.

[0142] Furthermore, according to the present invention, the amount of 5-MeO-DMT prodrugs and salts of 5-MeO-DMT prodrugs used is equimolar to the amount of the corresponding non-prodrug form.

[0143] Mode of administration

[0144] The therapeutically effective amount of 5-MeO-DMT is administered by inhalation, by nasal administration, by buccal administration, or by sublingual administration. Administration via these routes can ensure rapid onset of action. The most preferred route of administration is by inhalation. Preferably, the therapeutically effective amount of 5-MeO-DMT is inhaled in a single breath.

[0145] For nasal administration, 5-MeO-DMT can be used as a pure substance or in the form of a nasal administration formulation, examples of which are known in the art. For nasal administration, 5-MeO-DMT can be used as a pharmaceutically acceptable salt (preferably the hydrobromide salt) or in the form of a formulation of a pharmaceutically acceptable salt (preferably the hydrobromide salt). Examples of suitable devices are known in the art.

[0146] Buccal or sublingual administration may also rely on a pharmaceutically acceptable salt of 5-MeO-DMT, preferably the hydrobromide salt, itself or in the form of a formulation, such as a tablet, film, spray, cream, as is known in the art.

[0147] Administration is particularly carried out by inhalation of an aerosol. This aerosol comprises (a) a pharmaceutically acceptable gas; (b) aerosol particles of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof, wherein the aerosol has an aerosol particle mass density of about 0.5 mg / l to about 18 mg / l, such as about 0.5 mg / l to about 12.5 mg / l, preferably about 1.3 mg / l to about 10 mg / l, in particular about 2 mg / l to about 9 mg / l. The pharmaceutically acceptable gas is preferably air.

[0148] The aerosol particles preferably contain less than 1% by weight of impurities, in particular less than 0.5% by weight of impurities. In addition, they preferably contain less than 0.5% by weight of 5-MeO-DMT degradation products, in particular less than 0.2% by weight of 5-MeO-DMT degradation products, which are produced by chemical modifications of 5-MeO-DMT as a result of chemical reactions during aerosol formation.

[0149] In a further preferred aspect, the aerosol consists essentially of: (a) air; (b) aerosol particles of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0150] The aerosol particles preferably contain 5-MeO-DMT in the free base form.

[0151] The aerosol is preferably characterised by having a mass median aerodynamic diameter of less than 3 μm and greater than 0.1 μm, in particular less than 2 μm and greater than 0.1 μm.

[0152] The aerosol can be formed by a) exposing a thin layer of 5-MeO-DMT or a pharmaceutically acceptable salt thereof disposed on a solid support to thermal energy, and b) passing air through the thin layer of 5-MeO-DMT to generate aerosol particles. The thin layer can have a thickness of less than about 10 μm, particularly less than about 7.5 μm. The thin layer can have a thickness in the range of about 0.1 μm to about 10 μm, particularly in the range of about 0.3 μm to about 7.5 μm.

[0153] A thin layer of 5-MeO-DMT disposed on a solid support can be exposed to thermal energy via air passing through the thin layer. Alternatively, a thin layer of 5-MeO-DMT disposed on a solid support can be exposed to thermal energy via the solid support.

[0154] The air passing through the thin layer may have a temperature in the range of about 180° C. to about 260° C. The air passing through the thin layer may in particular have a temperature of about 210° C. and pass through the thin layer at a rate of about 12 l / min for about 15 seconds.

[0155] The aerosol particles may be contained in a volume equal to or less than about 3 liters, in particular contained in a volume of about 1 to about 3 liters, such as about 2 to about 3 liters. Delivery to the patient is preferably via a single inhalation.

[0156] 5-MeO-DMT or a pharmaceutically acceptable salt thereof is provided in a form suitable for inhalation in a medical setting. 5-MeO-DMT and a pharmaceutically acceptable salt thereof are provided in the form of an aerosol. These aerosols have a suitable aerosol particle mass density so that a therapeutically effective dose of the aerosol can be administered to a patient via a single inhalation.

[0157] Aerosols that can be used in the present invention can be formed using thermal energy. When using thermal energy to form an aerosol of a compound, it is difficult to predict which conditions are suitable for safe, efficient and predictable aerosolization, particularly when the aerosol is to be used for systemic delivery of the compound to a patient via the lungs. The relevant variables in this context include a) the dosage of the compound, b) the morphological state (e.g., crystalline form or thin layer form) of the compound that can be used for aerosolization, c) the amount of thermal energy to which the compound is exposed (defined by temperature and exposure duration) and d) the volume (defined by flow rate and airflow duration) of the air introduced to form the aerosol.

[0158] The compositions and methods described herein are used to safely, efficiently, and predictably deliver 5-MeO-DMT or a pharmaceutically acceptable salt thereof to a patient systemically by inhalation. "Safe" means that the aerosol particles should contain only minimal amounts of impurities and 5-MeO-DMT degradation products, "efficient" means that the dose is aerosolized to a specified extent, preferably almost completely aerosolized or completely aerosolized, i.e., the aerosol has the desired physical properties so that the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is delivered systemically via the lungs primarily via absorption in the alveoli, and the patient can inhale the aerosol in a single inhalation (i.e., within one deep breath), and "predictable" means that there is little or no variation in the amount of degradation products, the degree of aerosolization, and the physical properties of the aerosol.

[0159] A suitable aerosol can be achieved by a) providing a therapeutically effective amount of 5-MeO-DMT in the form of a thin layer on a solid support, b) exposing the thin layer of 5-MeO-DMT to an elevated controlled temperature for a short period of time, and c) providing a controlled amount of air such that an aerosol is formed.

[0160] A composition for delivering a therapeutically effective amount of 5-MeO-DMT may comprise an aerosol, wherein the aerosol is formed by: a) exposing a thin layer of 5-MeO-DMT disposed on a solid support to thermal energy, and b) passing air through the thin layer of 5-MeO-DMT; wherein the aerosol has one or more of the following characteristics: 1) it contains aerosol particles characterized by a mass median aerodynamic diameter of less than 3 microns, 2) it contains aerosol particles characterized by less than 1% by weight impurities and less than 0.5% 5-MeO-DMT degradation products, and 3) it can be delivered to a patient via a single inhalation.

[0161] An aerosol volume deliverable to a patient via a single inhalation that is characterized by a mass median aerodynamic diameter of less than 3 microns, less than 1 weight percent impurities, and less than 0.5 weight percent 5-MeO-DMT drug degradation products can be generated by defining the following: a) the dose of 5-MeO-DMT contained in the thin layer of 5-MeO-DMT, b) the thickness of the thin layer of 5-MeO-DMT, c) the thermal energy to which the thin layer of 5-MeO-DMT is exposed (defined by the temperature and the duration of exposure), and d) the total amount of air that passes through the thin layer of 5-MeO-DMT (defined by the airflow rate and the duration of airflow).

[0162] Preferably, the 5-MeO-DMT thin layer is exposed to thermal energy via air passing through the thin layer, in which case the air is heated. The heated air passing through the thin layer may have a temperature in the range of about 180° C. to about 260° C. The air passing through the thin layer may particularly have a temperature of about 210° C.

[0163] Alternatively, the thin layer of 5-MeO-DMT is exposed to thermal energy via a solid support, in which case the air passing through the thin layer is not heated, but the solid support is heated. The heated solid support may have a temperature in the range of about 180°C to about 420°C.

[0164] Preferably, the 5-MeO-DMT used to form the thin layer on the solid support is of high purity, at least 99%, preferably at least 99.5%.

[0165] Preferably, the dosage of 5-MeO-DMT contained in the thin layer of 5-MeO-DMT disposed on the solid support is from about 1 mg to about 25 mg, preferably from about 2 mg to about 20 mg, and more preferably from about 4 mg to about 20 mg. Useful specific amounts are, for example, about 4 mg, about 6 mg, about 8 mg, about 10 mg, about 12 mg, about 14 mg, about 16 mg, about 18 mg, and about 20 mg. Preferred specific amounts are, for example, about 6 mg, about 12 mg, and about 18 mg.

[0166] The solid support on which 5-MeO-DMT or a pharmaceutically acceptable salt thereof is provided can have a variety of shapes. Examples of such shapes include, but are not limited to, cylinders having a diameter of less than 1.0 mm, boxes having a thickness of less than 1.0 mm, and nearly any shape that is full of small holes (e.g., less than 1.0 mm in size). Preferably, the solid support provides a large surface area to volume ratio (e.g., greater than 100 / m) and a large surface area to mass ratio (e.g., greater than 1 cm 2 / gram).

[0167] A solid support of one shape can also be transformed into another shape with different properties. For example, a flat sheet with a thickness of 0.25 mm has a surface area to volume ratio of about 8,000 / meter. Rolling the sheet into a hollow cylinder with a diameter of 1 cm produces a support that retains the high surface area to mass ratio of the original sheet, but has a lower surface area to volume ratio (about 400 / meter).

[0168] A variety of different materials are used to construct the solid support. Classes of such materials include, but are not limited to, metals, inorganic materials, carbonaceous materials, and polymers. The following are examples of material classes: aluminum, silver, gold, stainless steel, copper, and tungsten; silicon dioxide, glass, silicon, and aluminum oxide; graphite, porous carbon, carbon yarn, and carbon felt; polytetrafluoroethylene and polyethylene glycol. Combinations of materials and coating variations of materials may also be used.

[0169] When aluminum is used as a solid support, aluminum foil is a suitable material. Examples of silica, alumina, and silicon-based materials include amorphous silica S-5631 (Sigma, St. Louis, Mo.), BCR171 (Aldrich, St. Louis, Mo.), and a crystalline silica having a defined surface area greater than 2 m 2 / g of aluminum oxide) and silicon wafers used in the semiconductor industry. Carbon yarn and carbon felt are available from American Kynol, Inc., New York, NY.

[0170] Preferably, the thickness of the 5-MeO-DMT layer disposed on the solid support is less than about 10 μm, in particular less than about 7.5 μm. The layer may have a thickness in the range of about 0.1 μm to about 10 μm, in particular in the range of 0.3 μm to 7.5 μm.

[0171] Preferably, the total amount of air passing through the 5-MeO-DMT thin layer is limited to about 6 liters / minute to about 40 liters / minute, preferably about 8 liters / minute to about 16 liters / minute of flow velocity, and the duration of the air flow is selected so that the cumulative volume of the aerosol is no more than about 3 liters, preferably about 1 liter to 3 liters, such as 2 liters to 3 liters.For example, when the air flow rate is about 6 liters / minute, the air flow duration should be less than about 30 seconds.A useful specific air flow rate and duration are about 12 liters / minute and about 15 seconds, thereby produce about 3 liters of aerosol volume.Another useful specific air flow rate and duration are 10 liters / minute and about 15 seconds, thereby produce about 2.5 liters of aerosol volume.Another useful specific air flow rate and duration are 8 liters / minute and about 15 seconds, thereby produce about 2 liters of aerosol volume.Another useful specific air flow rate and duration are 10 liters / minute and about 12 seconds, thereby produce about 2 liters of aerosol volume.

[0172] The aerosol formation rate is greater than 0.1 mg / second.

[0173] The aerosol has an aerosol particle mass density of about 0.5 mg / l to about 18 mg / l, such as about 0.5 mg / l to about 12.5 mg / l, preferably about 1.3 mg / l to about 10 mg / l, in particular about 2 mg / l to about 9 mg / l.

[0174] The 5-MeO-DMT aerosol particles are characterized by a mass median aerodynamic diameter of less than 3 microns and greater than 0.1 microns, preferably less than 2.5 microns and greater than 0.1 microns, most preferably less than 2 microns and greater than 0.1 microns. The 5-MeO-DMT aerosol particles are characterized by less than 1% by weight impurities, preferably less than 0.5% by weight impurities.

[0175] The 5-MeO-DMT aerosol particles are characterized by less than 0.5 wt % 5-MeO-DMT degradation products, preferably less than 0.2 wt % 5-MeO-DMT degradation products.

[0176] A composition for delivering a therapeutically effective amount of 5-MeO-DMT may comprise an aerosol, wherein the aerosol is formed by: a) exposing a 12 mg dose of 5-MeO-DMT configured as a thin layer less than 5 microns thick on a solid support to a temperature of 210° C. for 15 seconds by passing heated air through the thin layer; wherein the aerosol has one or more of the following characteristics: 1) it contains aerosol particles characterized by a mass median aerodynamic diameter of less than 3 microns, 2) it contains aerosol particles characterized by less than 1% impurities and less than 0.5% by weight of 5-MeO-DMT degradation products, and 3) it can be delivered to a patient via a single inhalation.

[0177] Those skilled in the art who understand the aerosol characteristics and aerosolization conditions defined in the present invention can determine suitable gasification devices or systems, which result in desired aerosol characteristics. Examples of such suitable gasification devices or systems include, for example, Volcano Medic gasification systems (Storz & Bickel, Germany) with associated dosing capsules with a drip pad; disclosed in, for example, EP 0 933 093 B1 and EP 1 884 254 B1 and registered community design 003387299-0001) and Staccato devices (Alexza Pharmaceuticals, Mountain View, USA; disclosed in, for example, US 7,458,374 B2, US 9,370,629 B2 and US 9,687,487 B2). The generated aerosol can be collected in the balloon and inhaled by the patient from the balloon.

[0178] Dosage regimen

[0179] The present invention also provides dosage ranges, specific dosages, and dosing regimens (administration regimens).

[0180] The present invention is based in part on the inventors' conclusion that the peak psychedelic experience occurs during the acute phase following administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof, which drives the therapeutic benefit of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof, in patients suffering from psychomotor retardation, particularly one or more aspects as defined above, either causally or at least as a surrogate behavioral marker of a potential unknown therapeutic mechanism.

[0181] Therefore, achieving peak experience more quickly in a greater proportion of patients and with better reproducibility in individual patients will lead to a better therapeutic profile than with previously tested psychedelics and dosing regimens.

[0182] Furthermore, the present invention also relies on the short duration of action of 5-MeO-DMT and the absence of associated tolerance (i.e., the absence of waning or loss of psychedelic effects upon re-administration) as a basis for enabling a dosing regimen of frequent re-administration (such as more than once daily or once daily) designed to increase the incidence of peak experiences, thereby increasing therapeutic benefit. Such repeated administrations over a short period of time also allow for intra-individual dose optimization, which reduces the risk of overdose, which may otherwise result in physical side effects such as serotonin syndrome, negative psychotic reactions (such as flashbacks of the experience at a later time point), induction of mania or hypomania, or less meaningful psychedelic experiences with little or no memory of the altered state (so-called "whiteouts"). Furthermore, starting with a low dose allows the patient to become familiar with the general psychedelic experience and allows for preparation for the more intense symptoms that occur at higher doses, which will have a positive impact on the experience at the higher doses. Furthermore, the prospect of being able to begin treatment at a low dose will increase patient acceptance of the treatment approach and improve overall compliance rates at the patient population level.

[0183] Frequent re-administration of serotonergic psychedelics to increase the frequency and modulate the repeatability of peak experiences and to enhance therapeutic efficacy, reduce side effects, and improve compliance rates may not be possible with other psychedelics due to the late onset and prolonged duration of psychedelic effects and the rapid development of tolerance (i.e., diminished or absent psychedelic effects following re-administration) that may persist for several days.

[0184] A patient suffering from psychomotor retardation as defined herein is treated by administering 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0185] In a preferred embodiment, 5-MeO-DMT is administered as monotherapy, ie, the patient is not receiving any other treatment for psychomotor retardation.

[0186] The dosage of 5-MeO-DMT administered to a patient suffering from psychomotor retardation as defined herein is in the range of about 1 mg to about 25 mg, or any amount within the range, preferably about 2 mg to about 20 mg, more preferably about 4 mg to about 20 mg. Useful specific amounts are, for example, about 4 mg, about 6 mg, about 8 mg, about 10 mg, about 12 mg, about 14 mg, about 16 mg, about 18 mg, and about 20 mg. Patients may also be treated with an equimolar dose of a pharmaceutically acceptable salt of 5-MeO-DMT, such as the hydrobromide salt. Please note that in this specification, when a range is listed (such as "about 1 mg to about 25 mg"), the inventors contemplate all discrete values ​​within the range, some of which are explicitly mentioned, but not all of them - this is simply for the purpose of brevity.

[0187] In a preferred embodiment, the improved method of treating a patient suffering from psychomotor retardation as defined herein using a therapeutically effective amount of 5-MeO-DMT comprises the onset of a clinical response no later than about 2 hours after administration of the 5-MeO-DMT.

[0188] In preferred embodiments, improved methods of treating patients suffering from psychomotor retardation as defined herein with a therapeutically effective amount of 5-MeO-DMT include a sustained clinical response, including a clinical response that occurs no later than about 2 hours after administration of 5-MeO-DMT, until at least about 6 days after the last administration of 5-MeO-DMT, preferably until at least about 14 days after the last administration of 5-MeO-DMT, and more preferably until at least about 28 days after the last administration of 5-MeO-DMT.

[0189] In a preferred embodiment, the improved method of treating a patient suffering from psychomotor retardation as defined herein with a therapeutically effective amount of 5-MeO-DMT comprises administering more than a single dose of 5-MeO-DMT.

[0190] In a preferred embodiment, the more than single dose of 5-MeO-DMT is administered to the patient in one or more treatment blocks, each block consisting of 2 to 7 administrations, the interval between each administration within each treatment block is no less than about 1 hour and no more than about 24 hours, and the interval between the end of one treatment block and the beginning of the next treatment block is no less than about 6 days.

[0191] In an even more preferred embodiment, the more than single dose of 5-MeO-DMT is administered to the patient in one or more treatment blocks, each block consisting of 1 to 3 administrations, the interval between each administration within each treatment block is about 24 hours, and the interval between the end of one treatment block and the beginning of the next treatment block is no less than about 6 days.

[0192] In a most preferred embodiment, the more than single dose of 5-MeO-DMT is administered to the patient in one or more treatment blocks, each block consisting of 1 to 3 administrations, the interval between each administration within each treatment block is about 1 to 4 hours, preferably 1 to 2 hours, and the interval between the end of one treatment block and the beginning of the next treatment block is no less than about 6 days.

[0193] In an embodiment, the dose of 5-MeO-DMT administered to an individual patient in each administration and each treatment block is constant for that individual patient and is selected from about 1 mg to about 25 mg, preferably about 2 mg to about 20 mg, more preferably about 4 mg to about 20 mg. Useful specific amounts are, for example, about 4 mg, about 6 mg, about 8 mg, about 10 mg, about 12 mg, about 14 mg, about 16 mg, about 18 mg, and about 20 mg.

[0194] In a preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient is selected from about 2 mg to about 8 mg at the first administration within each treatment block and then increased with each subsequent administration within each treatment block until 20 mg is reached, or all administrations within that treatment block have been administered, whichever is earlier.

[0195] In an even more preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient is selected from about 2 mg to about 8 mg at the first administration within each treatment block and is then increased with each subsequent administration within each treatment block until the earlier of: 20 mg is reached, or all administrations within that treatment block have been administered, or the patient experiences a peak psychedelic experience, or the attending physician determines that further increases in the dose are inappropriate based on observed side effects.

[0196] For embodiments where the dose of a subsequent administration is increased, the dose of the next administration is determined by adding about 2 mg to about 10 mg, preferably about 4 mg to about 8 mg, and most preferably about 6 mg to the dose of the previous administration. For example, if the first administered dose is 6 mg and the dose increase is 6 mg, the second administered dose is 12 mg unless one of the aforementioned stopping criteria has been met. Preferably, the third administered dose is 18 mg.

[0197] In a preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient in each treatment block is selected from about 2 mg to about 8 mg at the first administration, and then increased to a dose selected from about 8 mg to about 14 mg at the second administration, and to a dose selected from about 14 mg to about 20 mg at the third administration, unless the patient has experienced a peak psychedelic experience within the treatment block or the attending physician determines that further increases in the dose are inappropriate based on observed side effects. Useful specific amounts for the first, second, and third administrations are, for example, about 6 mg, about 12 mg, and about 18 mg.

[0198] In a further preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient at the first administration in a first treatment block is selected from about 2 mg to about 8 mg, and then increased with each subsequent administration within the first treatment block until the earlier of: reaching 20 mg, or all administrations within the treatment block have been administered, or the patient has experienced a peak psychedelic experience, or the attending physician determines that further increases in the dose are inappropriate based on observed side effects, wherein the highest dose in the first treatment block will be used as the dose for all subsequent treatment blocks and administrations within those subsequent treatment blocks. For example, if the highest dose in the first treatment block is 18 mg, because the patient experienced a peak psychedelic experience at that dose, then the dose for all subsequent treatment blocks and administrations within those subsequent treatment blocks is 18 mg.

[0199] In a most preferred embodiment, the dose of 5-MeO-DMT administered to an individual patient at the first administration in the first treatment block is selected from about 2 mg to about 8 mg, and then unless the patient has experienced a peak psychedelic experience within the treatment block or the attending physician decides that further increases in dose are inappropriate based on observed side effects, the second administration in the first treatment block will be increased to a dose selected from about 8 mg to about 14 mg, and the third administration in the first treatment block will be increased to a dose selected from about 14 mg to about 20 mg, wherein the highest dose in the first treatment block will be used as the dose for all subsequent treatment blocks and administrations within those subsequent treatment blocks. Useful specific amounts for the first, second, and third administrations in the first treatment block are, for example, about 6 mg, about 12 mg, and about 18 mg.

[0200] It will be appreciated that pharmaceutically acceptable salts of 5-MeO-DMT may also be used in all of the above dosing regimens and that the appropriate weight of the salt to be administered may be calculated based on the specified weight of the free base, assuming equimolar amounts are used.

[0201] According to the present invention, 5-MeO-DMT is preferably not administered together with a MAO inhibitor.

[0202] Patients can be identified as having a "peak psychedelic experience" by achieving at least 60% of the maximum possible score on each of the four subscales (mystical, positive emotions, transcendence of time and space, and ineffable) of the 30-item Revised Mystical Experience Questionnaire (MEQ-30) (as described in Barrett FS, J Psychopharmacol. 2015;29(11):1182-90).

[0203] Whether a patient has a “peak psychedelic experience” can also be determined by achieving at least 60% of the maximum possible score on the Oceanic Nothingness (OBN) dimension of the Altered States of Consciousness (ASC) Questionnaire (as described in Roseman L et al., Front Pharmacol. 2018;8:974).

[0204] According to the present invention, whether a patient has a "peak psychedelic experience" is preferably determined by achieving at least 75 points in the total score of the Peak Experience Scale (PES), which is also called the Peak Psychedelic Experience Questionnaire (PPEQ), which calculates the average score of the patient's answers to the following three questions from 0 to 100: 1. How intense was the experience; 2. How much loss of control was there; 3. How significant (i.e., profound and important) was the experience?

[0205] Treatment of psychomotor retardation and sleep disturbances

[0206] Sleep disturbances are conditions that affect the quality, timing, or duration of sleep, either idiopathically or in the context of a medical condition (e.g., psychiatric or neurological disorder). Sleep disturbances affect a person's ability to function normally while awake and are associated with patterns of high negative affect and low positive affect.

[0207] There are two basic types of sleep: rapid eye movement (REM) sleep and non-REM sleep. Non-REM sleep can be divided into four stages (I-IV). These non-REM stages correspond to increasing depth of sleep. Non-REM and REM sleep alternate during the four to five cycles of normal human sleep each night. During the early part of the night, non-REM sleep is deeper and occupies a disproportionately large amount of time, especially in the first sleep cycle. As the night progresses, non-REM sleep becomes lighter, and more of each cycle is allocated to REM sleep.

[0208] Normal, healthy sleep consists of the different stages described above, which proceed in a continuous, strictly controlled sequence throughout the night.

[0209] Disruptions in this tight control can lead to sleep disturbances.

[0210] Common forms of sleep disturbances include disorders of falling asleep and maintaining sleep (insomnias), disorders of excessive sleepiness (hypersomnias), disorders of the sleep-wake schedule (circadian rhythm disorders), disorders related to sleep, sleep stages, or partial arousals (parasomnias), disorders characterized by disturbed breathing during sleep (sleep-related breathing disorders), and disorders characterized by abnormal movements during sleep (sleep-related movement disorders). In a broad sense, fatigue can also be considered a sleep disturbance.

[0211] Insomnia is a sleep disorder in which the patient has difficulty falling asleep or staying asleep. People with insomnia have trouble falling asleep; wake up frequently during the night and have difficulty falling asleep again; wake up too early in the morning; have poor sleep quality; and / or have at least one daytime problem due to poor sleep quality, such as fatigue, sleepiness, mood problems, difficulty concentrating, accidents at work or while driving, etc.

[0212] Hypersomnia is characterized by excessive daytime sleepiness and / or prolonged sleep at night. Sleep drunkenness is also a symptom found in patients with hypersomnia. Transitioning from sleep to wakefulness is difficult. Individuals who experience sleep drunkenness report being confused, disoriented, sluggish, and falling asleep again and again upon waking.

[0213] Circadian rhythm disorders are characterized by chronic or recurrent sleep disturbances due to alterations in an individual's internal circadian rhythm or due to inconsistencies between their circadian rhythm and their desired or required work or social schedules. This desynchronization may be temporary or persistent. The ensuing clinical presentation combines symptoms of insomnia and hypersomnia. Sleep duration is often shortened and interrupted, performance in the desired wakefulness state is impaired, and restoration of a normal sleep schedule is temporarily impossible.

[0214] Parasomnias refer to various forms of sleep disorders characterized by people experiencing unusual behaviors or physiological activities (such as sleepwalking or nightmares) before falling asleep, during sleep, or during the arousal period between sleep and wakefulness. There is considerable variability in characteristics, severity, and frequency. Parasomnias may impair sleep quality.

[0215] Sleep-related breathing disorders are characterized by abnormal and difficult breathing during sleep. Breathing is a complex process that relies heavily on the coordinated action of the respiratory muscles and the brain. These sleep disturbances may have a serious impact on sleep and the balance of oxygen and carbon dioxide in the blood, manifesting as chronic snoring, sleep apnea, sleep-related hypoventilation, and / or hypoxemia. In some of these disorders, breathing is also abnormal while awake. Reduced airflow leads to intermittent hypoxia, resulting in sleep fragmentation due to micro-arousals or awakenings. Inflammation and endothelial dysfunction may occur, reducing vascular elasticity and increasing coagulation, predisposing individuals to atherosclerosis, which, together with reduced oxygenation, may lead to heart and brain damage.

[0216] In sleep-related movement disorders, repetitive, relatively simple, often stereotyped movements disrupt sleep or the onset of sleep. The most common of these are restless legs syndrome (RLS) and periodic limb movement disorder (PLMD).

[0217] Fatigue describes a state of weariness that is not relieved by rest or sleep. It is a feeling of tiredness, drowsiness, or decreased energy, usually characterized by a weakening or exhaustion of physical or mental resources, and is characterized by a reduced ability to work and a reduced efficiency in responding to stimuli. Fatigue is normal after a period of mental or physical exertion, but sometimes fatigue can occur in the absence of such exertion and is a symptom of a health condition.

[0218] Inadequate sleep quantity or quality may lead to personality changes and may not only exacerbate existing mental illness but also serve as a precipitant for its development.

[0219] Elderly people are particularly susceptible to sleep disorders such as insomnia and circadian rhythm abnormalities. Severe and persistent sleep disturbances in elderly patients may lead to neuropsychiatric symptoms such as psychomotor retardation. Lack of sleep can also lead to the development of obesity, diabetes and heart disease, which can have a negative impact on life.

[0220] Treatment for sleep disorders varies depending on the type and underlying cause. Maintaining good sleep hygiene, a healthy sleep environment, and a consistent sleep-wake schedule are often considered first-line treatments. If unsuccessful, treatment may involve medication or psychotherapy.

[0221] Available treatments are not successful in all patients, may be associated with side effects and / or require long-term treatment to achieve a relevant therapeutic effect.

[0222] In patients suffering from sleep disturbances associated with psychiatric or neurological disorders, known treatments for the psychiatric or neurological disorders do not necessarily improve the sleep disturbances.

[0223] For example, sleep disorders are frequently associated with mental disorders such as depression. However, treating depression does not necessarily lead to improvements in accompanying sleep disorders. Although most antidepressants have been shown to affect sleep architecture, some classes of antidepressants improve sleep, while other antidepressants may cause impaired sleep (Hutka et al. Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment. Int J Mol Sci. 2021 January 29; 22(3): 1333., Abstract).

[0224] To assess sleep, parameters such as sleep duration, sleep architecture, sleep latency, and frequency and duration of wakefulness throughout the night can be measured. Quantitative indicators can be measured using objective methods, including polysomnography, actigraphy, and determination of sleep latency, or by self-report measurements (questionnaires).

[0225] Polysomnography is a technique that requires patients to be monitored throughout the night in a specialist clinic. Various functions are measured throughout the night, including eye movements, brain and muscle activity, breathing effort and airflow, blood oxygen levels, body posture and movement, snoring and heart rate.

[0226] Sleep latency can be measured using the Multiple Sleep Latency Test (MSLT). This test provides an objective measure to determine how long it takes a person to fall asleep after multiple test naps. An average sleep latency of about 10 minutes is considered normal; less than 8 minutes indicates a sleep disorder. An accompanying analysis of brain activity can help further diagnose a sleep disorder.

[0227] The sleep rating questionnaire captured ratings of components of sleep quality, such as perception of sleep depth, difficulty in waking up, and rest after sleep, as well as other factors that may affect sleep quality, such as comorbid conditions and medication use.

[0228] Assessment of qualitative aspects of the sleep experience is important because sleep discomfort may often persist despite normal values ​​on quantitative sleep measures.

[0229] Questionnaires not only facilitate rapid and accurate assessment of complex clinical problems but may also be useful for tracking the patient's progress. Therefore, self-reported sleep questionnaires completed by patients are an important basis for the assessment of sleep disturbances in clinical practice.

[0230] A variety of sleep quality indices are known. The following indices include examples of questionnaires for assessing general sleep and examples of questionnaires for assessing insomnia, hypersomnia, circadian rhythm disorders and parasomnias, respectively. However, the present invention is not limited to the use of a particular index or questionnaire.

[0231] For example, general sleep quality can be assessed using the Sleep Quality Scale (SQS) and the Sleep-50 questionnaire.

[0232] The Sleep Quality Scale (SQS) is an all-encompassing assessment tool that implements a universal, efficient measure suitable for assessing sleep quality in a variety of patient and study populations. Individual questions about daytime symptoms, such as problems with attention, difficulty concentrating or remembering (item 15 “Poor sleep makes it hard for me to think,” item 19 “Poor sleep causes me to make mistakes at work,” item 21 “Poor sleep makes it easier for me to forget things,” item 22 “Poor sleep makes it hard for me to concentrate at work”), recovery after sleep, problems falling asleep and staying asleep, difficulty awakening, and sleep satisfaction can be scored from 0 (“rarely”) to 3 (“almost always”), with higher scores indicating more severe sleep problems.

[0233] The Sleep-50 questionnaire consists of 50 items designed to screen for various types of sleep disorders in the general population. The scale consists of nine subscales reflecting some of the most common disorders and discomforts associated with sleep and factors required for diagnosis, such as sleep apnea, insomnia, narcolepsy, restless legs / periodic leg movement disorder, circadian rhythm sleep disorders, sleepwalking, nightmares, factors affecting sleep, and the impact of sleep discomfort on daily function. For each item, the respondent is given a scale from 1 ("not at all") to 4 ("very much") and is asked to indicate the extent to which the statement matches their experience in the last month or another appropriate recall window.

[0234] The questionnaire requires that in order to diagnose a sleep disorder, not only a specific subscale (e.g., insomnia) but also the affect subscale must exceed a certain cut-off point (Spoormaker et al. Initial validation of the SLEEP-50 questionnaire. Behav Sleep Med. 2005; 3(4):227-46., optimal cut-off values ​​and scoring procedures in Table 4).

[0235] Treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score below a cut-off value.

[0236] A commonly used questionnaire to assess sleep disturbance is the Pittsburgh Sleep Quality Index. Other tools are the Insomnia Severity Index and the Espie Sleep Disturbance Questionnaire.

[0237] The Pittsburgh Sleep Quality Index (PSQI) assesses overall sleep quality and sleep disturbances. The PSQI is a 19-question self-rating questionnaire that asks respondents to indicate how often they have experienced certain sleep difficulties in the past month or another appropriate recall window.

[0238] Nineteen self-rated questions assess multiple factors related to sleep quality, including estimates of sleep duration and latency and estimates of the frequency and severity of specific sleep-related problems. The 19 items are divided into seven component scores: (1) subjective sleep quality; (2) sleep latency; (3) sleep duration; (4) habitual sleep efficiency; (5) sleep disturbances; (6) use of sleeping pills; and (7) daytime dysfunction.

[0239] Each component is scored from 0 to 3. Higher scores indicate more severe sleep disturbance. A detailed scoring description of the Pittsburgh Sleep Quality Index can be found in the appendix of Buysse et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May; 28(2): 193-213.

[0240] The seven component scores are then summed to create an overall score ranging from 0-21, with "0" indicating no difficulty and "21" indicating severe difficulty in all areas. A total score cutoff of 5 distinguishes those with poor sleep quality from those with good sleep quality. A total score of >5 indicates that the patient has severe difficulty in at least two areas, or moderate difficulty in more than three areas.

[0241] If the PSQI is used to assess treatment outcomes, treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score to 5 or less.

[0242] The Insomnia Severity Index (ISI) is a 5-item questionnaire that addresses subjective sleep quality, symptom severity, subjective satisfaction with sleep, the degree of interference of insomnia with daily functioning (item 3, “To what extent do you think your sleep problems interfere with your daily functioning (e.g., daytime fatigue, functioning at work / daily chores, concentration, memory, mood, etc.)”), how significant the respondent feels their insomnia is compared to other people, and the overall level of distress caused by sleep problems. Individual responses can be scored from 0 (=none) to 4 (=very much); higher total scores correspond to more severe insomnia. A total score of 0-7 indicates "no clinically significant insomnia," 8-14 means "subthreshold insomnia," 15-21 means "clinical insomnia (moderate severity)," and 22-28 means "clinical insomnia (severe)" (A. Shahid et al. (eds.), STOP, THAT and One Hundred Other Sleep Scales, Springer Science+Business Media, LLC 2012; Bastien et al. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307).

[0243] The typical recall window for ISI is two weeks, but other appropriate recall windows may be used herein.

[0244] Treatment success is indicated by (i) a decrease in the score, for example a decrease of >7 points, particularly >8 points; preferably (ii) a decrease in the score to below the cut-off value for clinically significant insomnia.

[0245] The Espie Sleep Disturbance Questionnaire (SDQ) evaluates the subjective experience of insomnia. The SDQ assesses restlessness / agitation, mental overactivity, consequences of insomnia, and lack of sleep preparation, with a particular focus on beliefs about the root causes of sleep problems. Respondents use a five-point scale to indicate how often certain statements about insomnia represent their experiences. 1 means "never true," and 5 means "often true." The higher the score, the more abnormal the belief in the causes and related factors of insomnia (A. Shahid et al., loc. cit.; Espie et al. Insomniacs'attributions. psychometric properties of the Dysfunctional Beliefs and Attitudes about Sleep Scale and the Sleep Disturbance Questionnaire. J Psychosom Res. 2000 February; 48 (2): 141-8).

[0246] A decrease in the score indicates successful treatment.

[0247] Excessive sleeping or excessive sleepiness can be assessed using the Epworth Sleepiness Scale, the Stanford Sleepiness Scale, or the Idiopathic Hypersomnia Severity Scale.

[0248] The Epworth Sleepiness Scale (ESS) assesses overall daytime sleepiness. The questionnaire asks respondents to rate their likelihood of falling asleep in eight different situations, representing moments of relative inactivity, such as an afternoon nap or sitting in a car stopped in traffic. Respondents rate their likelihood of falling asleep using a 0-3 scale (0 means "never doze off" and 3 means "very likely to doze off"). Scores range from 0-24; the higher the score, the greater the severity of daytime sleepiness. A cutoff score of 10 indicates that daytime sleepiness may occur at the clinical level (A. Shahid et al., loc. cit. Johns et al., A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep, December 1991; 14 (6): 540-5).

[0249] Treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score to 10 or less.

[0250] The Stanford Sleepiness Scale is a subjective measure of sleepiness that evaluates the degree of sleepiness at a particular moment. The scale consists of only one item, requiring respondents to select one of seven statements that best represents their current perceived sleepiness level. The degree of sleepiness is assessed using a scale ranging from 1 (=feeling active and energetic; alert; fully awake) to 7 (=almost in a fantasy; falling asleep quickly; unable to stay awake) (A. Shahid et al., loc. cit.; Hoddes et al. The development and use of the Stanford sleepiness scale (SSS). Psychophysiology, 1972, 9, 150).

[0251] A decrease in the score indicates successful treatment.

[0252] Parasomnias can be assessed using the Paris Arousal Disorders Severity Scale (PADSS).

[0253] The Paris Arousal Disorders Severity Scale (PADSS) is a self-rating scale that lists parasomnias, assesses their frequency, and includes an evaluation of their consequences (Arnulf et al. A scale for assessing the severity of arousal disorders. Sleep. 2014 Jan 1;37(1):127-36).

[0254] Treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score below a cut-off value.

[0255] A commonly used questionnaire for assessing sleep-related breathing disorders is the Berlin Questionnaire (A. Shahid et al., loc. cit.; Netzer et al., Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999 Oct 5; 131(7):485-91). An appropriate recall period may also be selected.

[0256] A decrease in the score indicates successful treatment.

[0257] A commonly used questionnaire for assessing sleep-related movement disorders is the International Restless Legs Syndrome Study Group Rating Scale (A. Shahid et al., loc. cit.; Walters et al.; International Restless Legs Syndrome Study Group 2003. Validation of the International Restless Legs Syndrome Study Group ratingscale for restless legs syndrome. Sleep Medicine 4(2), pp. 121-132).

[0258] The response to treatment can be assessed by a decrease in the score.

[0259] Fatigue is often assessed, for example, by the FACES (fatigue, weakness, awareness, energy, sleepiness) scale.

[0260] The FACES (fatigue, weakness, consciousness, energy, sleepiness) rating scale is a 50-item list for distinguishing between tiredness, sleepiness, and fatigue. Respondents use a scale from 0 ("not at all") to 3 ("strongly") to indicate the extent to which they experienced each feeling or energy state in the previous week or another appropriate recall period. The higher the score, the more severe the tiredness or fatigue state, except for the items belonging to the energy subscale (A. Shahid et al., loc. cit.; Shapiro et al., Development of an adjective checklist to measure five FACES of fatigue and sleepiness. Data from a national survey of insomniacs. J Psychopomp Res. 2002 June; 52 (6): 467-73).

[0261] Effective treatment may reduce tiredness and / or fatigue scores and / or increase energy subscale scores.

[0262] The treatment response can be evaluated by the above-mentioned quantitative measurements (such as polysomnography or wrist actigraphy) and / or using the above-mentioned questionnaires. A significant decrease or increase in the total score, or a significant decrease in the prevalence, frequency and impact on daily functioning, respectively, according to the corresponding sleep scale, indicates a treatment-induced improvement in sleep disturbances.

[0263] A common test that may be used to assess psychomotor retardation or aspects thereof is the Salpêtrière Retardation Rating Scale (SRRS).

[0264] Resting-state fMRI has been widely used in patients with sleep disorders to enhance the understanding of pathophysiology and potential compensatory mechanisms.

[0265] Alterations in resting-state networks can be identified in insomnia, hypersomnia, circadian rhythm disorders, parasomnias, sleep-related breathing disorders, and sleep-related movement disorders.

[0266] In patients with insomnia, functional connectivity impairments were observed within the default mode network (DMN) and within the salience network, which are associated with the detection and integration of emotional and sensory stimuli. Studies have shown that these networks contain key areas for the integration of emotional and physical states, and that functional connectivity impairments within and / or between these networks and other brain regions may account for patients' alertness, subjective distress, and poor sleep continuity.

[0267] For example, sleep deprivation in healthy subjects leads to altered functional connectivity within and / or between the default mode network, dorsal attention network, and salience network, and these brain functional connectivity changes somewhat resemble the vulnerability patterns seen in patients with Alzheimer's disease.

[0268] The default mode network is affected in patients with hypersomnia. For example, in idiopathic hypersomnia, different DMN hubs (precuneus and medial prefrontal cortex) show significant changes, and functional connectivity in the DMN is associated with self-reported severity of sleepiness.

[0269] A study investigating differences between night-shift nurses and day-shift nurses revealed that circadian rhythm disturbances promote changes in resting-state function in the cerebellum, involved in sleep regulation and cognitive functions such as responsiveness and alertness. In addition, functional connectivity of the DMN is fundamentally different in early and late circadian rhythm phenotypes. As with other forms of sleep disturbance, circadian rhythm disturbances can lead to changes in brain functional connectivity. Changes in resting-state brain functional connectivity have been reported in various diseases with circadian rhythm disturbances.

[0270] Although performing functional brain imaging during parasomnia events is technically difficult, differences in the precuneus have been observed in disorders of arousal representative of non-REM parasomnias.

[0271] The precuneus is involved in the analysis and integration of visual, auditory and somatosensory information and the monitoring of movement. The precuneus is a subregion of the DMN. Therefore, the default mode network is affected in patients with parasomnias.

[0272] Resting-state fMRI studies in patients with sleep-related breathing disorders such as obstructive sleep apnea (OSA) have shown that chronic exposure to oxidative stress, intermittent hypoxia, hypocapnia and hypercapnia, and sleep fragmentation, some of the main causes of brain damage in OSA, may lead to severe global and regional connectivity deficits, especially in the default mode network (DMN) and regions involved in arousal and sensorimotor systems.

[0273] Sleep-related movement disorders, such as periodic limb movements during sleep, were reflected by alterations in the prefrontal motor control pathway, a subregion of the default mode network. In addition, activity in the cerebellum and thalamus was observed, as well as additional activation in the red nucleus and brainstem.

[0274] In many cases, abnormal functional connectivity of resting state networks involved in sleep regulation is also involved in psychomotor retardation. Therefore, according to the invention, influencing these networks by the therapy according to the invention will lead to an improvement in sleep disturbances and, if the patient being treated suffers from psychomotor retardation, also to an improvement in psychomotor retardation.

[0275] Clinical data from studies of patients with TRD or postpartum depression (PPD) demonstrate that sleep disturbances can be successfully treated.

[0276] In studies involving the administration of 5-MeO-DMT, the MADRS item “reduced sleep”, which reflects insomnia, was assessed, among others.

[0277] The MADRS item "Sleep reduction" represents the experience of reduced sleep duration or depth compared to the normal pattern of the subject's own health. When the subject's sleep is normal, the score is 0. A score of 2 reflects mild difficulty falling asleep, or slightly reduced, shallow or intermittent sleep time. A score of 4 means that sleep time is reduced or interrupted by at least two hours. A score of 6 means less than two or three hours of sleep.

[0278] In the study group that received the individualized dosing regimen, the total score for the MADRS item "reduced sleep" was 25 at baseline for all eight patients. On day 1 after treatment, the earliest time point at which the effect of treatment on sleep was assessed, the score decreased to 12, which corresponds to an improvement of 13 points or 52%. On day 7 after treatment, the score decreased to 9, which corresponds to an improvement of 16 points or 64%.

[0279] In the 12 mg group, the total score of the MADRS item "reduced sleep" for all 4 patients was 12 at baseline. On day 1 after treatment, the score dropped to 10, which corresponds to an improvement of 2 points or 17%. On day 7 after treatment, the score dropped to 6, which corresponds to an improvement of 6 points or 50%.

[0280] Thus, the score of the scale item "sleep loss" which is particularly related to sleep disturbance was significantly improved. The inventors concluded that 5-MeO-DMT can be used to treat sleep disturbance, especially in patients suffering from psychiatric disorders or nervous system disorders.

[0281] Treatment of patients suffering from sleep disorders, particularly insomnia, and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates psychomotor retardation and results in improvement of sleep disorders, particularly insomnia.

[0282] A reduction or elimination of psychomotor retardation in patients suffering from sleep disorders, particularly insomnia, is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0283] The reduction or elimination of psychomotor retardation in patients suffering from sleep disorders, in particular insomnia, occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from sleep disorders, in particular insomnia, preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0284] Reduction or elimination of psychomotor retardation in patients suffering from sleep disorders, particularly insomnia, is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0285] The reduction or elimination of psychomotor retardation in patients suffering from sleep disorders, in particular insomnia, at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS), occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from sleep disorders, in particular insomnia, at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS), preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0286] As mentioned above, psychomotor retardation is an important aspect of patients suffering from sleep disorders. Therefore, the improvement of psychomotor retardation will also lead to the improvement of sleep disorders. Since psychomotor retardation also affects other aspects of sleep disorders, the inventors conclude that the improvement of psychomotor retardation will further contribute to the overall improvement of sleep disorders (especially insomnia).

[0287] In the case of idiopathic sleep disorders in patients who also suffer from associated psychomotor retardation, the clinical response may be reflected by a reduction in the Clinical Global Impression - Severity (CGI-S) score. According to the present invention, a reduction in the CGI-S score means that the CGI-S is reduced by at least 1 point. Preferably, the CGI-S is reduced by at least 2 points and / or to 0 points. Particularly preferably, the CGI-S is reduced by at least 3 points and / or to 0 points.

[0288] Improvement in idiopathic sleep disturbance in patients also suffering from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, is observed on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0289] Improvement of idiopathic sleep disturbance in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S scores in patients also suffering from associated psychomotor retardation) occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of idiopathic sleep disturbance in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0290] In an embodiment, improvement in idiopathic sleep disorders in patients also suffering from associated psychomotor retardation is observed on the 7th day after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, as reflected in a decrease in the CGI-S score, and preferably persists until at least 14 days, more preferably until at least 28 days.

[0291] In the case of idiopathic sleep disorders in patients who also suffer from associated psychomotor retardation, improvement in the sleep disorder (as reflected by a score of at least "much improved" in the Clinical Global Impression-Improvement (CGI-I) score or the Patient Global Impression-Improvement (PGI-I) score) preferably occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0292] In the case of idiopathic sleep disorders in patients who also suffer from associated psychomotor retardation, improvement in sleep disorders (reflected by a decrease in at least the "much improved" score in the CGI-I score or the PGI-I score) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0293] In the case of idiopathic sleep disorders in patients who also suffer from associated psychomotor retardation, improvement may also be assessed by any other scale reflecting changes in sleep quality or quantity as described above, such as the Pittsburgh Sleep Quality Index (PSQI).

[0294] If the PSQI is used to assess treatment outcomes, treatment success is indicated by (i) a decrease in the score, preferably (ii) a decrease in the score to 5 or less.

[0295] Improvement in idiopathic sleep disorders in patients who also suffer from associated psychomotor retardation (reflected by a decrease in PSQI scores, particularly a decrease to 5 or below) preferably occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, with the recall period extending from the time point after the last administration when the acute psychedelic experience subsides to the assessment time point.

[0296] This improvement in idiopathic sleep disorders in patients who also suffer from associated psychomotor retardation (reflected by a decrease in PSQI scores) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, wherein the recall period is from the time point at which the acute psychedelic experience after the last administration subsides to the assessment time point.

[0297] Improvements in idiopathic sleep disturbances in patients who also suffer from associated psychomotor retardation (reflected by a decrease in PSQI scores) are observed on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, wherein the recall period is from the time point at which the acute psychedelic experience has subsided after the last administration to the assessment time point.

[0298] Psychomotor retardation and sleep disturbances (especially insomnia) are closely related to mental and nervous system disorders. Both psychomotor retardation and sleep disturbances (especially insomnia) occur in mental or nervous system disorders, such as disorders characterized by depressive episodes, such as major depressive disorder (MDD); bipolar disorder (BD), such as bipolar disorder type I and bipolar disorder type II; postpartum depression (PPD); seasonal affective disorder and persistent depressive disorder; mental and behavioral disorders caused by the use of psychoactive substances, such as substance use disorders (SUD); psychotic disorders, such as schizophrenia; dementia, such as Alzheimer's disease dementia (AD); Lewy body dementia (DLB); vascular dementia and Parkinson's disease dementia; Parkinson's disease (PD); chronic fatigue syndrome.

[0299] Treatment according to the invention will result in improvement of psychomotor retardation and sleep disturbances, in particular insomnia, and related psychiatric or neurological disorders, examples of which are listed above.

[0300] Treatment of psychomotor retardation and mental and neurological disorders

[0301] For patients suffering from psychomotor retardation associated with a psychiatric disorder or a nervous system disorder, treatment of psychomotor retardation according to the present invention may improve the symptoms associated with the psychomotor retardation.

[0302] Although psychomotor retardation can be considered a condition that deserves treatment, independent of any other condition, disorder, or symptom an individual may have, a variety of psychiatric and neurological disorders are associated with psychomotor retardation. It is important to note that the relationship between psychomotor retardation and psychiatric disorders is bidirectional. Not only can psychiatric disorders negatively affect the psychomotor retardation of patients, but psychomotor retardation can also be a contributing factor to the development, progression, and prognosis of psychiatric or neurological disorders.

[0303] In many cases, resting-state networks involved in psychomotor retardation are also involved in the disorders listed above.

[0304] 5-MeO-DMT has the ability to disrupt established functional connectivity patterns of resting state networks. This disruption results in a reset of pathological, poorly connected brain connections as the network rewires. New, healthy functional connections are established, and this has a lasting effect.

[0305] Disorders characterized by depressive episodes

[0306] Several disorders are characterized by depressive episodes.

[0307] A depressive episode is a period of depressed mood and / or loss of interest in most activities.

[0308] For example, according to DSM-V, a major depressive episode is characterized by the presence of five or more symptoms within the same 2-week period and the symptoms represent a change from previous functioning; at least one of the symptoms is (1) depressed mood or (2) loss of interest or pleasure, and includes symptoms such as psychomotor retardation.

[0309] Patients suffering from a disorder characterized by depressive episodes may suffer from a treatment-resistant form of the disorder.

[0310] Patients with disorders characterized by depressive episodes may experience psychomotor retardation.

[0311] Psychomotor retardation is included in the diagnostic criteria for disorders characterized by depressive episodes. It can be assessed as part of the HAM-D or MADRS test.

[0312] The Montgomery-Asberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS scores indicate more severe depression.

[0313] The items are overt sadness; reported sadness; inner tension; decreased sleep; loss of appetite; difficulty concentrating; laziness; sluggishness; pessimistic thoughts; and suicidal thoughts, and each item is scored from 0 to 6. The total score ranges from 0 to 60.

[0314] The MADRS item “sluggishness” indicates difficulty starting or slowness in initiating and performing daily activities.

[0315] A score of 0 means almost no difficulty in getting started and no slowness. If the patient has trouble starting an activity, the score is 2. A score of 4 means difficulty starting simple daily activities that require effort. If the patient is completely lazy and cannot do anything without help, the score is 6.

[0316] This MADRS scale item is particularly relevant to psychomotor retardation, i.e., decreased energy and activity and reduced motivation.

[0317] The Hamilton Depression Rating Scale (HAM-D) can help clinicians assess the nature and severity of mood disturbances in a patient population. The scale consists of 21 items, but only the first 17 items (depressed mood; guilt; suicidality; initial insomnia; nighttime insomnia; delayed insomnia; work and interest; retardation; agitation; mental anxiety; physical anxiety; gastrointestinal somatic symptoms; general somatic symptoms; genital symptoms; hypochondriasis; weight loss; insight) are used for scoring.

[0318] For most questions, the score ranges from 0 to 4, with 4 representing more severe signs of depression. A few questions extend the range to only 2. A total score is calculated, which can then be compared to previous scores or contrasted to a predefined cutoff score.

[0319] In the context of the “retardation” item, the questionnaire assessed slowness of thinking and speech, impaired attention, and reduced motor activity.

[0320] Psychomotor retardation in patients suffering from a disorder characterized by depressive episodes can be further assessed, for example, using the Salpêtrière Retardation Rating Scale (SRRS).

[0321] In patients with disorders characterized by depressive episodes, altered functional connectivity within and / or between several brain regions associated with processing, regulation, emotional memory, cognitive processes related to rumination, impaired concentration, and physiological arousal is observed.

[0322] Treatment of patients suffering from a disorder characterized by depressive episodes (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT, or a pharmaceutically acceptable salt thereof, reduces or eliminates the psychomotor retardation and results in improvement of the disorder characterized by depressive episodes.

[0323] A reduction or elimination of psychomotor retardation in a patient suffering from a disorder characterized by a depressive episode is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0324] The reduction or elimination of psychomotor retardation in a patient suffering from a disorder characterized by a depressive episode occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in a patient suffering from a disorder characterized by a depressive episode preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0325] A reduction or elimination of psychomotor retardation, particularly laziness, in a patient suffering from a disorder characterized by a depressive episode is reflected in at least an improvement in the score for the MADRS item "laziness" at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0326] The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from a disorder characterized by a depressive episode (reflected by an improvement in the score of the MADRS item "laziness") occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (reflected by an improvement in the score of the MADRS item "laziness") in patients suffering from a disorder characterized by a depressive episode preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0327] Alternatively or additionally, reduction or elimination of psychomotor retardation, particularly retardation, in a patient suffering from a disorder characterized by a depressive episode is reflected in at least an improvement in the score of the HAM-D item retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0328] The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from a disorder characterized by a depressive episode (reflected by an improvement in the score of the HAM-D item retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from a disorder characterized by a depressive episode (reflected by an improvement in the score of the HAM-D item retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0329] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from a disorder characterized by a depressive episode is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0330] The reduction or elimination of psychomotor retardation in patients suffering from a disorder characterized by a depressive episode (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from a disorder characterized by a depressive episode (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0331] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from a disorder characterized by a depressive episode is reflected in at least an improvement in the mean score on a Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0332] The reduction or elimination of psychomotor retardation in patients suffering from a disorder characterized by a depressive episode (at least as reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from a disorder characterized by a depressive episode (at least as reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0333] As described above, psychomotor retardation is closely related to disorders characterized by depressive episodes. Therefore, improvements in psychomotor retardation will also lead to improvements in disorders characterized by depressive episodes. Since psychomotor retardation also affects other aspects of disorders characterized by depressive episodes, the inventors conclude that improvements in psychomotor retardation will further contribute to the overall improvement of disorders characterized by depressive episodes.

[0334] Improvements in disorders characterized by depressive episodes in patients who also suffer from associated psychomotor retardation, as reflected by reductions in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0335] The improvement of the disorder characterized by depressive episodes in patients who also suffer from associated psychomotor retardation (reflected by a decrease in the CGI-S score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The improvement of the disorder characterized by depressive episodes in patients who also suffer from associated psychomotor retardation (reflected by a decrease in the CGI-S score) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0336] Major depressive disorder (MDD) is a mood disorder that causes persistent feelings of sadness and loss of interest. MDD affects a person's feelings, thoughts, and behaviors and can lead to a variety of emotional and physical problems.

[0337] Patients suffering from MDD may suffer from a treatment-resistant form of the disorder.

[0338] The patient may suffer from a treatment-resistant disease. Treatment resistance means that the patient has not adequately improved after at least two adequate courses of treatment. The patient has not adequately improved, in particular, after at least two adequate courses of treatment, wherein at least one of the two courses is drug therapy; for example, the patient has not adequately improved after at least two adequate courses of drug therapy. In particular, at least two previous courses of treatment were administered in the current episode of the disease.

[0339] Psychomotor retardation is a core feature of major depressive disorder (MDD) and is one of the nine symptoms listed in the DSM-V that identify MDD.

[0340] Clinical manifestations of psychomotor retardation in MDD include abnormal speech, decreased eye contact and eye movements, and poor posture.

[0341] The presence of psychomotor retardation may help guide treatment planning, as there is evidence that tricyclic antidepressants (TCAs) may provide a better response than selective serotonin reuptake inhibitors (SSRIs) in these cases.

[0342] Psychomotor retardation may be associated with more severe symptoms. A study of 291 patients with MDD found that those with higher lifetime psychomotor retardation scores had more severe depression.

[0343] Psychomotor retardation in patients suffering from MDD can be assessed as part of the HAM-D or MADRS assay. Psychomotor retardation, or at least aspects thereof, can also be assessed, for example, by using the Salpêtrière Slowness Rating Scale (SRRS) or the Motor Agitation and Retardation Scale (MARS).

[0344] MDD can be characterized by dysfunctional functional connectivity and regulation within and / or between multiple resting-state networks, including the DMN, salience network, executive control network, limbic network, and somatomotor network. Functional connectivity is significantly different from that observed in healthy controls.

[0345] Treatment of patients suffering from MDD (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of the MDD.

[0346] Patients may have moderate or severe MDD, as indicated by a Montgomery-Asberg Depression Rating Scale (MADRS) score of 20 or higher, or a Hamilton Depression Rating Scale (HAM-D) score of 17 or higher. It is further considered that patients may have severe major depressive disorder, as indicated by a Montgomery-Asberg Depression Rating Scale (MADRS) score of 35 or higher, or a Hamilton Depression Rating Scale (HAM-D) score of 25 or higher.

[0347] A reduction or elimination of psychomotor retardation in a patient suffering from MDD is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0348] The reduction or elimination of psychomotor retardation in patients suffering from MDD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from MDD preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0349] A reduction or elimination of psychomotor retardation, particularly laziness, in patients suffering from MDD is reflected in at least an improvement in the score of the MADRS item "laziness" at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on the first day, for example, about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on the 7th day; on the 14th day; and / or on the 28th day after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0350] The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from MDD (reflected by an improvement in the score of the MADRS item "laziness") occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from MDD (reflected by an improvement in the score of the MADRS item "laziness") preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0351] Alternatively or additionally, reduction or elimination of psychomotor retardation, particularly psychomotor retardation, in patients suffering from MDD is reflected in at least an improvement in the score of the HAM-D item retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0352] The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from MDD (reflected by an improvement in the score of the HAM-D item retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from MDD (reflected by an improvement in the score of the HAM-D item retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0353] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from MDD is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0354] The reduction or elimination of psychomotor retardation in patients suffering from MDD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from MDD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0355] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from MDD is reflected in at least an improvement in the mean score on a Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0356] The reduction or elimination of psychomotor retardation in patients suffering from MDD (at least as reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from MDD (at least as reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0357] As mentioned above, psychomotor retardation is closely related to MDD. Therefore, the improvement of psychomotor retardation will also lead to the improvement of MDD. Since psychomotor retardation also affects other aspects of MDD, the inventors conclude that the improvement of psychomotor retardation (particularly the alleviation or elimination of psychomotor retardation) will further contribute to the overall improvement of MDD.

[0358] Improvements in MDD in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0359] Improvement in MDD in patients who also suffer from associated psychomotor retardation (as reflected by a decrease in CGI-S scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement in MDD in patients who also suffer from associated psychomotor retardation (as reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0360] Compared to other psychedelic drugs (such as LSD, psilocybin, or DMT), 5-MeO-DMT or a pharmaceutically acceptable salt thereof may be preferably administered to patients suffering from MDD associated with psychomotor retardation using a dosing regimen as described herein without incurring a significant risk of inducing mania or hypomania.

[0361] Preferably, patients suffering from MDD associated with psychomotor retardation do not experience treatment-induced mania or hypomania.

[0362] Bipolar disorder (BD) is a mental health condition characterized by dramatic mood swings, including low moods (major depressive episodes) and high moods (manic or hypomanic episodes). Bipolar disorder is a relapsing, chronic disorder that affects more than 1% of the world's population, regardless of ethnic origin or socioeconomic status.

[0363] If at least one manic episode occurs (with or without a depressive episode), BD is classified as bipolar disorder type I. If at least one hypomanic episode (but not a full manic episode) and one major depressive episode occur, BD is classified as bipolar disorder type II. If these symptoms are caused by medications or medical problems, the symptoms are not diagnosed as bipolar disorder.

[0364] Patients suffering from BD (including bipolar disorder type I and bipolar disorder type II) may suffer from treatment-resistant forms of the disorder.

[0365] The patient may suffer from a treatment-resistant disease. Treatment resistance means that the patient has not adequately improved after at least two adequate courses of treatment. The patient has not adequately improved, in particular, after at least two adequate courses of treatment, wherein at least one of the two courses is drug therapy; for example, the patient has not adequately improved after at least two adequate courses of drug therapy. In particular, at least two previous courses of treatment were administered in the current episode of the disease.

[0366] Psychomotor retardation is a core feature of bipolar depression and is one of the nine symptoms listed in the DSM-V to identify a major depressive episode in the context of bipolar disorder.

[0367] A study comparing patients with bipolar depression and age-matched patients with unipolar depression found that at the same depression severity score, bipolar disorder had higher psychomotor retardation scores than unipolar depression patients.

[0368] Psychomotor retardation in patients suffering from BD can be assessed as part of the HAM-D or MADRS assay. Psychomotor retardation or at least aspects thereof can also be assessed, for example, by using the Salpêtrière Slowness Rating Scale (SRRS) or the Motor Agitation and Retardation Scale (MARS).

[0369] Patients with bipolar disorder display characteristic abnormalities in the intrinsic organization and interconnectivity of resting-state networks.

[0370] Resting-state functional magnetic resonance imaging studies have demonstrated altered functional connectivity of specific regions within and / or between the default mode network, the salience network, and the central executive network compared with healthy controls.

[0371] Treatment of patients suffering from BD (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of BD.

[0372] Typically, patients with BD, whether diagnosed with bipolar II or bipolar I, suffer from a current major depressive episode.

[0373] The severity of the current major depressive episode can be assessed using the Montgomery-Asberg Depression Rating Scale (MADRS). The patient may have a total score equal to or greater than 19, such as greater than or equal to 24, in particular greater than or equal to 37.

[0374] A reduction or elimination of psychomotor retardation in patients suffering from BD is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0375] The reduction or elimination of psychomotor retardation in a patient suffering from BD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in a patient suffering from BD preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0376] A reduction or elimination of psychomotor retardation, particularly laziness, in patients suffering from BD is reflected in at least an improvement in the score of the MADRS item "laziness" at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0377] The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from bipolar disorder (reflected by an improvement in the score of the MADRS item "laziness") occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (reflected by an improvement in the score of the MADRS item "laziness") in patients suffering from BD preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0378] Alternatively or additionally, reduction or elimination of psychomotor retardation, particularly retardation, in patients suffering from BD is reflected in at least an improvement in the score of the HAM-D item retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0379] The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from BD (reflected by an improvement in the score of the HAM-D item retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from BD (reflected by an improvement in the score of the HAM-D item retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0380] Alternatively or additionally, a reduction in psychomotor retardation in a patient suffering from BD is reflected in at least an improvement in a score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0381] The reduction or elimination of psychomotor retardation in patients suffering from BD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from BD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0382] Alternatively or additionally, a reduction in psychomotor retardation in a patient suffering from BD is reflected in at least an improvement in the mean score on a Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0383] The reduction or elimination of psychomotor retardation in patients suffering from BD (at least reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from BD (at least reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0384] As mentioned above, psychomotor retardation is closely related to BD. Therefore, the improvement of psychomotor retardation will also lead to the improvement of BD. Since psychomotor retardation also affects other aspects of BD, the inventors concluded that the improvement of psychomotor retardation will further contribute to the overall improvement of BD.

[0385] Improvements in BD in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0386] Improvement of BD in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of BD in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0387] Compared to other psychedelic drugs (such as LSD, psilocybin, or DMT), 5-MeO-DMT or a pharmaceutically acceptable salt thereof may be preferably administered to patients suffering from bipolar disorder associated with psychomotor retardation (such as bipolar disorder type I and bipolar disorder type II) using a dosing regimen as described herein without incurring a significant risk of inducing mania or hypomania.

[0388] Preferably, patients suffering from bipolar disorder associated with psychomotor retardation (such as bipolar disorder type I and bipolar disorder type II) do not experience treatment-induced mania or hypomania.

[0389] Postpartum depression (PPD) is a debilitating mood disorder that develops during pregnancy or within 4 weeks after childbirth. More than 50% of women may experience a brief period of low mood or tearfulness after childbirth, but a small percentage of women may develop PPD. Epidemiological studies estimate the prevalence of PPD to be about 15%.

[0390] Patients suffering from PPD may suffer from a treatment-resistant form of the disorder.

[0391] Postpartum depression is also defined as a major depressive episode that occurs within 4 weeks of childbirth. Psychomotor retardation is therefore a core feature of postpartum depression and is one of the 9 symptoms listed in the DSM-V to identify a major depressive episode.

[0392] Psychomotor retardation in patients suffering from PPD can be assessed as part of the HAM-D or MADRS assay. Psychomotor retardation or at least aspects thereof can also be assessed, for example, by the Salpêtrière Slowness Rating Scale (SRRS) or the Motor Agitation and Retardation Scale (MARS).

[0393] In patients with PPD, significant changes in neural activity in brain regions important for self-regulation, empathy, emotion, and cognition can be observed. PPD is associated with functional impairments in resting-state networks, such as within and / or between the default mode network and the frontoparietal network.

[0394] Treatment of patients suffering from PPD (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates psychomotor retardation and results in improvement of PPD.

[0395] Patients may have moderate or severe PPD, as indicated by a Montgomery-Asberg Depression Rating Scale (MADRS) score of 20 or higher, or a Hamilton Depression Rating Scale (HAM-D) score of 16 or higher. Further consideration is given to patients who may have severe PPD, as indicated by a Montgomery-Asberg Depression Rating Scale (MADRS) score of 35 or higher, or a Hamilton Depression Rating Scale (HAM-D) score of 27 or higher.

[0396] Patients treated according to the present invention may have a Montgomery-Asberg Depression Rating Scale (MADRS) score of 20 or higher or a 17-item Hamilton Depression Rating Scale (HAM-D) score of 16 or higher.

[0397] Furthermore, patients treated according to the present invention may have a MADRS score of 28 or higher or a HAM-D score of 22 or higher.

[0398] Furthermore, patients treated according to the present invention may have a MADRS score of 35 or higher or a HAM-D score of 25 or higher.

[0399] A reduction or elimination of psychomotor retardation in a patient suffering from PPD is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0400] The reduction or elimination of psychomotor retardation in a patient suffering from PPD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in a patient suffering from PPD preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0401] A reduction or elimination of psychomotor retardation, particularly laziness, in a patient suffering from PPD is reflected at least in an improvement in the score of the MADRS item "laziness" at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0402] The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from PPD (reflected as an improvement in the score of the MADRS item "laziness") occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from PPD (reflected as an improvement in the score of the MADRS item "laziness") preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0403] Alternatively or additionally, reduction or elimination of psychomotor retardation, particularly retardation, in patients suffering from PPD is reflected in at least an improvement in the score of the HAM-D item retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0404] The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from PPD (reflected by an improvement in the score of the HAM-D item retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from PPD (reflected by an improvement in the score of the HAM-D item retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0405] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from PPD is reflected in at least an improvement in the score on the Salpêtrière Retardation Rating Scale at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0406] The reduction or elimination of psychomotor retardation in patients suffering from PPD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from PPD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0407] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from PPD is reflected in at least an improvement in the mean score on a Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0408] The reduction or elimination of psychomotor retardation in patients suffering from PPD (at least as reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from PPD (at least as reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0409] As mentioned above, psychomotor retardation is closely related to PPD. Therefore, the improvement of psychomotor retardation will also lead to the improvement of PPD. Since psychomotor retardation also affects other aspects of PPD, the inventors conclude that the improvement of psychomotor retardation will further contribute to the overall improvement of PPD.

[0410] Improvements in PPD in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0411] Improvement in PPD (as reflected by a decrease in CGI-S score) in patients who also suffer from associated psychomotor retardation occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement in PPD (as reflected by a decrease in CGI-S score) in patients who also suffer from associated psychomotor retardation preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0412] Furthermore, psychomotor retardation can impair maternal functioning.

[0413] For example, the Barkin Index of Maternal Function (BIMF) can be used to assess maternal function. The index is designed to measure function within one year after childbirth. The BIMF is a 20-item self-report function measurement. Each item is scored from 0 to 6, making the maximum total score 120 points. The higher the score, the better the assessment of maternal function.

[0414] BIMF identifies key areas of maternal functioning during the postpartum period as: self-care, infant care, mother-child interaction, maternal psychological well-being, social support, management, and adjustment.

[0415] A BIMF score of 95 or below is considered herein to represent mild impairment in maternal functioning, a score of 80 or below is considered herein to represent impaired maternal functioning, and a score of 65 or below is considered herein to represent severe impairment in maternal functioning.

[0416] The inventors have determined that increased scores on the MADRS item "slouching" have a negative impact on two aspects of maternal functioning (maternal ability related to interaction with the infant and maternal self-care).

[0417] An increase in the MADRS item “laziness” score impaired self-care, psychological well-being, and management. Conversely, an improvement on this MADRS item led to an improvement in maternal functioning, particularly in the BIMF functional domains psychological well-being, social support, and / or management.

[0418] The inventors concluded that 5-MeO-DMT can be used to treat PPD patients to achieve improvement in psychomotor retardation, particularly reduction or elimination of laziness.

[0419] The inventors also concluded that reducing or eliminating laziness by treating PPD patients not only leads to a decrease in the total MADRS score, but also leads to an improvement in maternal functioning, as reflected by an increase in the BIMF score.

[0420] The BIMF total score is improved by 10% or more, preferably by 20% or more.

[0421] Improvement in maternal function in patients suffering from PPD is reflected in at least an improvement in BIMF total score on day 7; day 14; and / or day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0422] Improvement in maternal function in patients suffering from PPD (at least as reflected by improvement in BIMF total score) occurs no later than about 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement in maternal function (at least as reflected by improvement in BIMF total score) preferably persists until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0423] Compared to other psychedelic drugs (such as LSD, psilocybin, or DMT), 5-MeO-DMT or a pharmaceutically acceptable salt thereof may be preferably administered to patients suffering from PPD associated with psychomotor retardation using a dosing regimen as described herein without incurring a significant risk of inducing mania or hypomania.

[0424] Preferably, patients suffering from PPD associated with psychomotor retardation do not experience treatment-induced mania or hypomania.

[0425] Seasonal affective disorder is a mood disorder with a seasonal pattern, with symptoms typically starting in the fall and easing in the spring. Many people experience sadness, hopelessness, loss of interest in activities, fatigue, and social withdrawal.

[0426] Patients suffering from seasonal affective disorder may suffer from a treatment-resistant form of the disorder.

[0427] Compared with controls, patients with SAD showed significant season-independent impairments on tasks measuring working memory, cognitive processing speed, and motor speed.

[0428] It has been reported that depressed subjects have sensorimotor impairments compared with healthy controls.

[0429] It is generally believed that psychomotor symptoms associated with depressive mood affect not only the execution of motor responses but also the speed of thinking.

[0430] Seasonal affective disorder is associated with psychomotor retardation, as are depressive episodes that may meet DSM-V criteria for a major depressive episode.

[0431] Psychomotor retardation in patients suffering from seasonal affective disorder can be assessed as part of the HAM-D or MADRS assay. Psychomotor retardation or at least aspects thereof can also be assessed, for example, by the Salpêtrière Slowness Rating Scale (SRRS) or the Motor Agitation and Retardation Scale (MARS).

[0432] Resting-state activity involving sensorimotor, attention, and visual processing is altered in patients with seasonal affective disorder compared with healthy controls.

[0433] Treatment of patients suffering from seasonal affective disorder (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of the seasonal affective disorder.

[0434] A reduction or elimination of psychomotor retardation in patients suffering from seasonal affective disorder is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0435] The reduction or elimination of psychomotor retardation in patients suffering from seasonal affective disorder occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from seasonal affective disorder preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0436] A reduction or elimination of psychomotor retardation, particularly laziness, in patients suffering from seasonal affective disorder is reflected in at least an improvement in the score of the MADRS item "laziness" at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on the first day, for example, about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on the 7th day; on the 14th day; and / or on the 28th day after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0437] The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from seasonal affective disorder (reflected by an improvement in the score of the MADRS item "laziness") occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (reflected by an improvement in the score of the MADRS item "laziness") in patients suffering from seasonal affective disorder preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0438] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from seasonal affective disorder is reflected in at least an improvement in the score of the HAM-D item retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0439] The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from seasonal affective disorder (reflected by an improvement in the score of the HAM-D item retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from seasonal affective disorder (reflected by an improvement in the score of the HAM-D item retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0440] Alternatively or additionally, a reduction in psychomotor retardation in a patient suffering from seasonal affective disorder is reflected in at least an improvement in a score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0441] The reduction or elimination of psychomotor retardation in patients suffering from seasonal affective disorder (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from seasonal affective disorder (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0442] Alternatively or additionally, a reduction in psychomotor retardation in a patient suffering from seasonal affective disorder is reflected in at least an improvement in the mean score on a Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0443] The reduction or elimination of psychomotor retardation in patients suffering from seasonal affective disorder (at least as reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from seasonal affective disorder (at least as reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0444] As mentioned above, psychomotor retardation is closely related to seasonal affective disorder. Therefore, the improvement of psychomotor retardation will also lead to the improvement of seasonal affective disorder. Since psychomotor retardation also affects other aspects of seasonal affective disorder, the inventors conclude that the improvement of psychomotor retardation will further contribute to the overall improvement of seasonal affective disorder.

[0445] Improvements in seasonal affective disorder in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0446] Improvement in seasonal affective disorder in patients who also suffer from associated psychomotor retardation (as reflected by a decrease in CGI-S scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement in seasonal affective disorder in patients who also suffer from associated psychomotor retardation (as reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0447] Compared to other psychedelic drugs (such as LSD, psilocybin, or DMT), 5-MeO-DMT or a pharmaceutically acceptable salt thereof may be preferably administered to patients suffering from seasonal affective disorder associated with psychomotor retardation using a dosing regimen as described herein without incurring a significant risk of inducing mania or hypomania.

[0448] Preferably, patients suffering from seasonal affective disorder associated with psychomotor retardation do not experience treatment-induced mania or hypomania.

[0449] Persistent depressive disorder

[0450] Persistent depressive disorder, also called dysthymia, is a chronic form of depression. It is diagnosed if depression is present most of the time, most of the days, for at least 2 years. Any symptom-free period is less than 2 months.

[0451] To be depressed, two or more of the following symptoms must be present: 1. Hopelessness 2. Lack of energy or fatigue 3. Low self-esteem 4. Decreased sleep (insomnia) or increased sleep (hypersomnia) 5. Loss of appetite or overeating 6. Difficulty making decisions or concentrating.

[0452] Patients suffering from persistent depressive disorder may suffer from a treatment-resistant form of the disorder.

[0453] Persistent depressive disorder is characterized by the criteria for major depressive disorder according to DSM-V and may persist for 2 years.

[0454] Persistent depressive disorder is associated with psychomotor retardation, as are depressive episodes that may meet DSM-V criteria for a major depressive episode.

[0455] Psychomotor retardation in patients suffering from PDD can be assessed as part of the HAM-D or MADRS assay. Psychomotor retardation or at least aspects thereof can also be assessed, for example, by using the Salpêtrière Slowness Rating Scale (SRRS) or the Motor Agitation and Retardation Scale (MARS).

[0456] In patients with persistent depressive disorder, altered functional connectivity within and / or between several brain regions associated with processing, regulation, emotional memory, cognitive processes related to rumination, impaired concentration, and physiological arousal is observed.

[0457] Functional connectivity impairments were observed within and between the DMN, salience network, executive control network, and limbic network. Functional connectivity was significantly different from that observed in healthy controls.

[0458] Treatment of patients suffering from PDD (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of the PDD.

[0459] A reduction or elimination of psychomotor retardation in a patient suffering from PDD is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0460] The reduction or elimination of psychomotor retardation in a patient suffering from PDD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in a patient suffering from PDD preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0461] A reduction or elimination of psychomotor retardation, particularly laziness, in a patient suffering from PDD is reflected at least in an improvement in the score of the MADRS item "laziness" at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0462] The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from PDD (reflected as an improvement in the score of the MADRS item "laziness") occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly laziness) in patients suffering from PDD (reflected as an improvement in the score of the MADRS item "laziness") preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0463] Alternatively or additionally, reduction or elimination of psychomotor retardation, particularly psychomotor retardation, in patients suffering from PDD is reflected in at least an improvement in the score of the HAM-D item retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0464] The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from PDD (reflected by an improvement in the score of the HAM-D item retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation (particularly retardation) in patients suffering from PDD (reflected by an improvement in the score of the HAM-D item retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0465] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from PDD is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0466] The reduction or elimination of psychomotor retardation in patients suffering from PDD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from PDD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0467] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from PDD is reflected in at least an improvement in the mean score on a Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0468] The reduction or elimination of psychomotor retardation in patients suffering from PDD (at least reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from PDD (at least reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0469] As mentioned above, psychomotor retardation is closely related to PDD. Therefore, the improvement of psychomotor retardation will also lead to the improvement of PDD. Since psychomotor retardation can also affect other aspects of PDD, the inventors have concluded that the improvement of psychomotor retardation (particularly the alleviation or elimination of psychomotor retardation) will further contribute to the overall improvement of PDD.

[0470] Improvements in PDD in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0471] Improvement in PDD in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement in PDD in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0472] Compared to other psychedelic drugs (such as LSD, psilocybin, or DMT), 5-MeO-DMT or a pharmaceutically acceptable salt thereof may be preferably administered to patients suffering from persistent depressive disorder associated with psychomotor retardation using a dosing regimen as described herein without incurring a significant risk of inducing mania or hypomania.

[0473] Preferably, patients suffering from persistent depressive disorder associated with psychomotor retardation do not experience treatment-induced mania or hypomania.

[0474] Mental and behavioral disorders due to psychoactive substance use

[0475] Substance use disorder (SUD) is a mental disorder that affects a person's behavior, causing a person to lose control of their use of substances (such as legal or illegal drugs, alcohol, or medications). Symptoms can range from moderate to severe, and addiction is the most severe form of SUD.

[0476] Patients suffering from SUD may suffer from a treatment-resistant form of the disorder.

[0477] Psychomotor retardation occurs in patients with certain mental and behavioral disorders caused by the use of psychoactive substances.

[0478] Psychomotor retardation has been noted during methamphetamine withdrawal, and one study showed that female patients with methamphetamine use disorder were more likely to experience psychomotor retardation than male users.

[0479] A large study of people who regularly use cannabis found that psychomotor retardation was one of the most common symptoms of cannabis withdrawal, although the lifetime prevalence was only 1%.

[0480] Resting-state functional connectivity (rsFC) was found to be altered not only in patients with psychomotor retardation but also in patients with SUD.

[0481] Psychomotor retardation, or at least aspects thereof, may also be assessed, for example, by using the Salpêtrière Retardation Rating Scale (SRRS).

[0482] Treatment of patients suffering from SUD (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of the SUD.

[0483] A reduction or elimination of psychomotor retardation in a patient suffering from a SUD is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0484] The reduction or elimination of psychomotor retardation in patients suffering from SUD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from SUD preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0485] Reduction or elimination of psychomotor retardation in a patient suffering from SUD is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0486] The reduction or elimination of psychomotor retardation in patients suffering from SUD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from SUD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0487] As mentioned above, psychomotor retardation is an important aspect of patients suffering from SUD. Therefore, the improvement of psychomotor retardation will also lead to the improvement of SUD. Since psychomotor retardation also affects other aspects of SUD, the inventors conclude that the improvement of psychomotor retardation will further contribute to the overall improvement of substance use disorders.

[0488] Improvements in SUD in patients suffering from psychomotor retardation, as reflected by reductions in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0489] Improvement in SUD (as reflected by a decrease in CGI-S score) in patients suffering from psychomotor retardation occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement in psychomotor retardation (as reflected by a decrease in CGI-S score) in patients also suffering from SUD preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0490] Psychotic Disorders

[0491] Psychotic disorders are severe mental disorders that cause abnormalities in thinking and perception. Psychotic disorders are characterized by severe impairment of reality testing and behavioral changes, manifested by positive symptoms such as persistent delusions, persistent hallucinations, disorganized thinking (often manifested as disorganized speech), severely disorganized behavior, and experiences of passivity and control, and negative symptoms such as blunted or flattened emotions, avolition, and psychomotor disturbances.

[0492] Patients suffering from a psychotic disorder may suffer from a treatment-resistant form of the disorder.

[0493] DSM-V describes symptoms of psychomotor retardation, such as lack of language and motor responses, as a core feature that defines psychotic disorders. Schizophrenia is an example of a primary psychotic disorder with a prominent feature of psychomotor retardation.

[0494] Psychomotor retardation also occurs in other psychotic disorders, such as schizoaffective disorder.

[0495] Psychomotor retardation, or at least aspects thereof, may also be assessed, for example, by means of the Salpêtrière Retardation Rating Scale (SRRS).

[0496] Imaging the brains of patients with psychotic disorders using functional magnetic resonance imaging of resting-state networks revealed significant alterations in different regions within and / or between the central executive, default mode, and salience networks. Alterations in resting-state networks could be identified even in a patient group at risk for psychosis.

[0497] Treatment of patients suffering from a psychotic disorder (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in an improvement in the psychotic disorder.

[0498] A reduction or elimination of psychomotor retardation in a patient suffering from a psychotic disorder is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0499] The reduction or elimination of psychomotor retardation in a patient suffering from a psychotic disorder occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in a patient suffering from a psychotic disorder preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0500] Reduction or elimination of psychomotor retardation in a patient suffering from a psychotic disorder is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0501] The reduction or elimination of psychomotor retardation in patients suffering from psychotic disorders (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from psychotic disorders (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0502] As mentioned above, the occurrence of psychomotor retardation is an important disease aspect of patients suffering from psychotic disorders. Therefore, the improvement of psychomotor retardation will also lead to the improvement of psychotic disorders. Since psychomotor retardation also affects other aspects of psychotic disorders, the inventors concluded that the improvement of psychomotor retardation will further contribute to the overall improvement of psychotic disorders.

[0503] Improvements in psychotic disorders in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0504] Improvement of psychotic disorders in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of psychotic disorders in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0505] Compared to other psychedelic drugs (such as LSD, psilocybin, or DMT), 5-MeO-DMT or a pharmaceutically acceptable salt thereof may be preferably administered using a dosing regimen as described herein to patients suffering from a psychotic disorder characterized by mania or hypomania and associated with psychomotor retardation without incurring a significant risk of inducing mania or hypomania.

[0506] Preferably, patients suffering from a psychotic disorder characterized by mania or hypomania and associated with psychomotor retardation do not experience treatment-induced mania or hypomania.

[0507] Schizophrenia is a serious mental health condition characterized by disturbances in multiple mental patterns, including perception, self-experience, volition, emotion, and behavior. Psychomotor disturbances, including catatonia, may occur.

[0508] Patients suffering from schizophrenia may suffer from a treatment-resistant form of the disorder.

[0509] Psychomotor retardation and slowing are also core features of schizophrenia and are classified as one of the "negative symptoms" of the disorder. Manifestations range from slowed movements to severe catatonia.

[0510] There is evidence that psychomotor retardation is associated with more severe illness in schizophrenia and with declines in semantic and episodic memory.

[0511] Abnormal resting-state functional connectivity has been reported in individuals with schizophrenia, particularly within and / or between the default mode network, frontoparietal network, and salience network.

[0512] Psychomotor retardation, or at least aspects thereof, can be assessed, for example, by the Salpêtrière Retardation Rating Scale (SRRS).

[0513] Treatment of patients suffering from schizophrenia (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of schizophrenia.

[0514] A reduction or elimination of psychomotor retardation in a patient suffering from schizophrenia is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0515] The reduction or elimination of psychomotor retardation in patients suffering from schizophrenia occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from schizophrenia preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0516] Reduction or elimination of psychomotor retardation in a patient suffering from schizophrenia is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0517] The reduction or elimination of psychomotor retardation in patients suffering from schizophrenia (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from schizophrenia (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0518] As mentioned above, psychomotor retardation is closely related to schizophrenia. Therefore, the improvement of psychomotor retardation will also lead to the improvement of schizophrenia. Since psychomotor retardation also affects other aspects of schizophrenia, the inventors have concluded that the improvement of psychomotor retardation will further contribute to the overall improvement of schizophrenia.

[0519] Improvements in schizophrenia in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0520] Improvement of schizophrenia in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of schizophrenia in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0521] Compared to other psychedelic drugs (such as LSD, psilocybin, or DMT), 5-MeO-DMT or a pharmaceutically acceptable salt thereof may be preferably administered to patients suffering from schizophrenia associated with psychomotor retardation using a dosing regimen as described herein without incurring a significant risk of inducing mania or hypomania.

[0522] Preferably, patients suffering from schizophrenia associated with psychomotor retardation do not experience treatment-induced mania or hypomania.

[0523] dementia

[0524] Dementia is caused by abnormal changes in the brain that lead to a decline in cognitive abilities and affect behavior, perception, and relationships. The condition is generally characterized by a loss of memory, language, problem-solving, and other thinking abilities severe enough to interfere with daily life.

[0525] Psychomotor slowing is an important feature of dementia syndrome.

[0526] Psychomotor retardation, or at least aspects thereof, can be assessed, for example, by means of the Salpêtrière Retardation Rating Scale (SRRS).

[0527] As magnetic resonance imaging studies can show, dementia affects various functional and structural connectivity networks of the brain. Alterations within and / or between the default mode network (DMN), the salience network, and the central executive network (CEN) have been observed.

[0528] Treatment of patients suffering from dementia and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of the dementia.

[0529] A reduction or elimination of psychomotor retardation in a patient suffering from dementia is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0530] The reduction or elimination of psychomotor retardation in a patient suffering from dementia occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in a patient suffering from dementia preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0531] Reduction or elimination of psychomotor retardation in a patient suffering from dementia is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0532] The reduction or elimination of psychomotor retardation in patients suffering from dementia (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from dementia (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0533] As mentioned above, patients suffering from dementia will experience psychomotor retardation. Therefore, improvement of psychomotor retardation will also lead to improvement of dementia. Since psychomotor retardation also affects other aspects of dementia, the inventors concluded that improvement of psychomotor retardation will further contribute to the overall improvement of dementia.

[0534] Improvements in dementia in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0535] Improvement of dementia in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of dementia in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S score) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0536] Alzheimer's disease dementia (AD) is a highly prevalent neurodegenerative disorder with insidious onset and slow progression of cognitive deficits. The percentage of neurocognitive impairment attributed to Alzheimer's disease ranges from about 60% to more than 90%, depending on the setting and diagnostic criteria. Decline in learning ability and memory are early and predominant features, and the decline is progressive.

[0537] Psychomotor slowing is a key feature of dementia syndromes such as Alzheimer's disease. The pathological drivers of this phenomenon are likely to be slower perceptual-motor and decision-making processes.

[0538] A study of 148 patients with mild cognitive impairment and age-matched controls found that the presence of psychomotor retardation significantly increased the risk of developing Alzheimer's disease dementia.

[0539] Psychomotor retardation, or at least aspects thereof, can be assessed, for example, by means of the Salpêtrière Retardation Rating Scale (SRRS).

[0540] AD affects various functional and structural connectivity networks in the brain that are associated with the topography, clinical phenotype, and severity of the disease. Magnetic resonance imaging studies have shown that there are continuous structural and functional disconnections between brain regions, supporting the view that AD is a disconnection syndrome. In particular, alterations within and / or between the default mode network (DMN), salience network, and central executive network (CEN) have been observed in both AD patients and individuals at high risk of developing AD.

[0541] Therefore, influencing these networks by the therapy according to the invention will lead to an improvement in psychomotor retardation and will also lead to an improvement in AD symptoms.

[0542] Treatment of patients suffering from AD and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of Alzheimer's disease dementia.

[0543] A reduction or elimination of psychomotor retardation in a patient suffering from AD is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0544] The reduction or elimination of psychomotor retardation in patients suffering from AD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from AD preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0545] Reduction or elimination of psychomotor retardation in a patient suffering from AD is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0546] The reduction or elimination of psychomotor retardation in patients suffering from AD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from AD (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0547] As mentioned above, psychomotor retardation is an important aspect of patients suffering from AD. Therefore, the improvement of psychomotor retardation will also lead to the improvement of AD. Since psychomotor retardation also affects other aspects of AD, the inventors concluded that the improvement of psychomotor retardation will further contribute to the overall improvement of AD.

[0548] Improvements in AD in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0549] Improvement of AD in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of AD in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S score) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0550] Dementia with Lewy bodies (DLB) is a type of dementia characterized by changes in sleep, behavior, cognition, movement, and regulation of automatic body functions.

[0551] Psychomotor slowing plays a role in dementia with Lewy bodies (DLB). In DLB, psychomotor slowing may be caused by visual and attentional impairments, which can also lead to hallucinations. DLB is characterized by psychomotor impairments that are more severe than those in Alzheimer's disease.

[0552] Psychomotor retardation, or at least aspects thereof, can be assessed, for example, by means of the Salpêtrière Retardation Rating Scale (SRRS).

[0553] Alterations in resting state networks (RSNs) can be identified in patients with DLB. Functional MRI studies have shown alterations in functional connectivity within and / or between the default mode network, salience network, executive network, and basal ganglia / limbic network.

[0554] Treatment of patients suffering from DLB and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of DLB.

[0555] A reduction or elimination of psychomotor retardation in a patient suffering from DLB is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0556] The reduction or elimination of psychomotor retardation in patients suffering from DLB occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from DLB preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0557] Reduction or elimination of psychomotor retardation in a patient suffering from DLB is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0558] The reduction or elimination of psychomotor retardation in patients suffering from DLB, as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS), occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from DLB, as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS), preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0559] As mentioned above, psychomotor retardation is an important aspect of patients suffering from DLB. Therefore, the improvement of psychomotor retardation will also lead to the improvement of DLB. Since psychomotor retardation also affects other aspects of DLB, the inventors conclude that the improvement of psychomotor retardation will further contribute to the overall improvement of DLB.

[0560] Improvements in DLB in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0561] Improvement in DLB in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement in DLB in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S score) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0562] Vascular dementia is a common type of dementia characterized by problems with reasoning, planning, judgment, memory and other thinking processes. These problems are caused by brain damage caused by blocked blood flow to the brain.

[0563] According to the NINDS-AIREN (National Institute of Neurological Disorders and Stroke / International Association for Research and Education in Neuroscience) criteria, psychomotor retardation was emphasized as a clinical feature consistent with a possible vascular dementia diagnosis.

[0564] Psychomotor retardation is particularly common when vascular dementia affects subcortical areas.

[0565] Psychomotor retardation, or at least aspects thereof, can be assessed, for example, by using the Salpêtrière Retardation Rating Scale (SRRS).

[0566] Functional magnetic resonance imaging reveals alterations in the functional connectivity of resting-state networks after cerebrovascular injury. Patients with severe or mild vascular neurocognitive impairment show abnormal functional connectivity within the DMN and other resting-state networks.

[0567] Treatment of patients suffering from vascular dementia and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of the vascular dementia.

[0568] A reduction or elimination of psychomotor retardation in a patient suffering from vascular dementia is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0569] The reduction or elimination of psychomotor retardation in patients suffering from vascular dementia occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from vascular dementia preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0570] Reduction or elimination of psychomotor retardation in a patient suffering from vascular dementia is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0571] The reduction or elimination of psychomotor retardation in patients suffering from vascular dementia, as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS), occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from vascular dementia, as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS), preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0572] As mentioned above, psychomotor retardation is an important aspect of patients suffering from vascular dementia. Therefore, improvement of psychomotor retardation will also lead to improvement of vascular dementia. Since psychomotor retardation also affects other aspects of vascular dementia, the inventors concluded that improvement of psychomotor retardation will further contribute to the overall improvement of vascular dementia.

[0573] Improvements in vascular dementia in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0574] Improvement in vascular dementia in patients also suffering from associated psychomotor retardation (as reflected by a decrease in CGI-S score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement in vascular dementia in patients also suffering from associated psychomotor retardation (as reflected by a decrease in CGI-S score) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0575] Parkinson's disease dementia is characterized by changes in thinking and behavior in people diagnosed with Parkinson's disease. It is a disease characterized by the gradual onset of movement problems, with the most common symptoms being slowed movements, tremors at rest, and unsteady walking that may lead to falls.

[0576] Parkinson's disease dementia is also associated with psychomotor retardation.

[0577] The study showed the existence of functional reorganization of resting-state networks, which is essential for generating and maintaining efficient behavioral and cognitive performance in patients with Parkinson's disease dementia. L-dopa can improve the clinical status of Parkinson's patients and may affect the functional connectivity of resting-state networks in Parkinson's patients.

[0578] Treatment of patients suffering from Parkinson's disease dementia and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of the Parkinson's disease dementia.

[0579] A reduction or elimination of psychomotor retardation in a patient suffering from Parkinson's disease dementia is observed on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0580] The reduction or elimination of psychomotor retardation in patients suffering from Parkinson's disease dementia occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from Parkinson's disease dementia preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0581] Improvements in psychomotor retardation in patients suffering from Parkinson's disease dementia, as reflected by a decrease in CGI-S scores, are observed on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0582] The improvement of psychomotor retardation in patients suffering from Parkinson's disease dementia (reflected by a decrease in CGI-S score) occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The improvement of psychomotor retardation in patients suffering from Parkinson's disease dementia (reflected by a decrease in CGI-S score) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0583] Reduction or elimination of psychomotor retardation in patients suffering from Parkinson's disease dementia is reflected in an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14 and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0584] The reduction or elimination of psychomotor retardation in patients suffering from Parkinson's disease dementia, as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS), occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from PDD, as reflected by an improvement in the Salpêtrière Slowness Rating Scale (SRRS), preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0585] As mentioned above, psychomotor retardation is an important aspect of Parkinson's disease dementia. Therefore, improvement of psychomotor retardation will also lead to improvement of Parkinson's disease dementia. Since psychomotor retardation also affects other aspects of Parkinson's disease dementia, the inventors concluded that improvement of psychomotor retardation will further contribute to the overall improvement of Parkinson's disease dementia.

[0586] Improvements in Parkinson's disease dementia in patients also suffering from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed on day 1, e.g., about 24 hours later; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0587] Improvement of Parkinson's disease dementia in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of Parkinson's disease dementia in patients who also suffer from associated psychomotor retardation (reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0588] Parkinson's disease

[0589] Parkinson's disease (PD) is a disorder characterized by the gradual onset of movement problems, the most common symptoms being slowed movements, tremors at rest, and unsteady walking that may lead to falls.

[0590] Psychomotor retardation is a cardinal feature of subcortical disorders such as Parkinson's disease (PD).

[0591] Psychomotor retardation, or at least aspects thereof, can be assessed, for example, by using the Salpêtrière Retardation Rating Scale (SRRS) or the Digit Symbol Substitution Test (DSST).

[0592] Analyses of resting-state networks using functional magnetic resonance imaging have shown that Parkinson's disease-related cognitive deficits are associated with altered connectivity patterns within and / or between resting-state functional connectivity networks, such as the default mode network, dorsal attention network, or frontoparietal network.

[0593] Treatment of patients suffering from PD and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of PD.

[0594] A reduction or elimination of psychomotor retardation in a patient suffering from PD is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0595] The reduction or elimination of psychomotor retardation in patients suffering from PD occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from PD preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0596] Reduction or elimination of psychomotor retardation in a patient suffering from PD is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0597] The reduction or elimination of psychomotor retardation in patients suffering from PD (reflected by an improvement in the score of the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from PD (reflected by an improvement in the score of the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0598] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from PD is reflected in at least an improvement in a score on a Digit Symbol Substitution Test (DSST) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0599] The reduction or elimination of psychomotor retardation in patients suffering from PD (reflected by an improvement in the score on the Digit Symbol Substitution Test (DSST)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from PD (reflected by an improvement in the score on the Digit Symbol Substitution Test (DSST)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0600] As mentioned above, psychomotor retardation is an important aspect of patients suffering from PD. Therefore, the improvement of psychomotor retardation will also lead to the improvement of PD. Since psychomotor retardation also affects other aspects of PD, the inventors concluded that the improvement of psychomotor retardation will further contribute to the overall improvement of PD.

[0601] Improvements in psychomotor retardation in patients suffering from PD, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0602] Improvement of psychomotor retardation in patients suffering from PD (reflected by a decrease in CGI-S scores) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of psychomotor retardation in patients also suffering from PD (reflected by a decrease in CGI-S scores) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0603] Chronic fatigue syndrome

[0604] Fatigue describes a feeling of exhaustion, listlessness, and decreased energy. Fatigue occurs when a person's physical or mental resources become weak or depleted. Although it is considered normal to experience fatigue after a period of mental or physical exertion, fatigue can occur in the absence of such exertion and is a symptom of a health condition.

[0605] In addition, chronic fatigue that is exacerbated by activity is a cardinal symptom of chronic fatigue syndrome, a disorder in which severe fatigue is accompanied by neurocognitive, autonomic, and immune symptoms.

[0606] Multiple abnormalities in normal sleep patterns have been reported in patients with chronic fatigue syndrome that may serve as maintaining factors.

[0607] Symptoms of chronic fatigue syndrome also include psychomotor slowing.

[0608] Patients with chronic fatigue syndrome showed abnormal resting-state functional connectivity, which was significantly correlated with the severity of their chronic fatigue.

[0609] Treatment of patients suffering from chronic fatigue syndrome (including treatment-resistant forms of the disorder) and associated psychomotor retardation with 5-MeO-DMT or a pharmaceutically acceptable salt thereof reduces or eliminates the psychomotor retardation and results in improvement of chronic fatigue syndrome.

[0610] A reduction or elimination of psychomotor retardation in patients suffering from chronic fatigue syndrome is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0611] The reduction or elimination of psychomotor retardation in patients suffering from chronic fatigue syndrome occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from chronic fatigue syndrome preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0612] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from chronic fatigue syndrome is reflected in at least an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS) at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0613] The reduction or elimination of psychomotor retardation in patients suffering from chronic fatigue syndrome (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from chronic fatigue syndrome (at least as reflected by an improvement in the score on the Salpêtrière Slowness Rating Scale (SRRS)) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0614] Alternatively or additionally, reduction or elimination of psychomotor retardation in a patient suffering from chronic fatigue syndrome is reflected in at least an improvement in the mean score of a Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on day 7; on day 14; and / or on day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0615] The reduction or elimination of psychomotor retardation in patients suffering from chronic fatigue syndrome (at least reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. The reduction or elimination of psychomotor retardation in patients suffering from chronic fatigue syndrome (at least reflected by an improvement in the mean score of the Motor Agitation and Slowness Scale (MARS) subscale associated with motor retardation) preferably lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0616] As mentioned above, psychomotor retardation is closely related to chronic fatigue syndrome. Therefore, the improvement of psychomotor retardation will also lead to the improvement of chronic fatigue syndrome. Since psychomotor retardation can also affect other aspects of chronic fatigue syndrome, the inventors have concluded that the improvement of psychomotor retardation (particularly the reduction or elimination of psychomotor retardation) will further contribute to the overall improvement of chronic fatigue syndrome.

[0617] Improvements in chronic fatigue syndrome in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in CGI-S scores, are observed at about 2 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 1, e.g., about 24 hours after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof; at day 7; at day 14; and / or at day 28 after the last administration of 5-MeO-DMT, or a pharmaceutically acceptable salt thereof.

[0618] Improvement of chronic fatigue syndrome in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S score) occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof. Improvement of chronic fatigue syndrome in patients also suffering from associated psychomotor retardation (reflected by a decrease in CGI-S score) preferably persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

[0619] Example

[0620] The following examples are set forth to aid in the understanding of the present invention and are not intended to, and should not be construed to, limit the invention described in the claims that follow in any manner.

[0621] Example 1-5 - MeO-DMT Aerosol Generation and Administration

[0622] Step 1: Prepare a stock solution of 5-MeO-DMT free base in 100% ethanol in a volumetric flask so that a 200 μl solution volume contains the target dose of 5-MeO-DMT free base to be administered to the volunteer or patient via inhalation. A typical target dose is 1 mg to 25 mg 5-MeO-DMT. For example, for a target dose of 18 mg 5-MeO-DMT, dissolve 90 mg of 5-MeO-DMT in 100% ethanol in a final solution volume of 1 ml. Aliquots of the stock solution can then be stored in vials until further use.

[0623] Step 2: 200 μl of the solution was transferred into a dosing capsule (Storz & Bickel, Germany) containing a drip pad and then the lid of the dosing capsule was closed.

[0624] Step 3: The dosing capsules filled with the 5-MeO-DMT ethanol solution were transferred to the filling chamber of the first Volcano Medic vaporizer, which was preheated and set to 55°C. The gas flow of the vaporizer was then turned on for 60 seconds at a preset rate of approximately 12 l / min. The heated air would flow through the dosing capsules, allowing the ethanol to evaporate, while the target dose of 5-MeO-DMT remained in the capsules as a thin layer covering the stainless steel mesh. The accurate preparation of the dosing capsules was confirmed by demonstrating that the final weight gain of the capsules was approximately equal to the target dose of 5-MeO-DMT compared to the empty capsule weight.

[0625] Step 4: The prepared dosing capsule is removed from the filling chamber. It is then transferred to the filling chamber of a second VolcanoMedic vaporizer, which has been preheated and set to 210°C with the airflow turned on for at least 5 minutes and then turned off immediately before transfer. A valved inhalation balloon (Storz & Bickel, Germany) is mounted on the socket of the filling chamber, the filling chamber is tightly closed, and the airflow is immediately turned on at a preset flow rate of approximately 12 l / min for 15 seconds and then turned off. This will allow the entire dose of 5-MeO-DMT to be aerosolized and distributed in the approximately 3 liters of air in the inhalation balloon. Accurate aerosolization of 5-MeO-DMT can be confirmed by demonstrating that the capsule weight has returned to approximately its initial weight.

[0626] Step 5: The balloon is then disconnected from the filling chamber, which automatically closes the valve. After the mouthpiece is connected to the balloon, the aerosol is ready to be immediately administered to the volunteer or patient.

[0627] Step 6: To prepare for administration, ask the patient to first take 1-2 deep breaths, exhale completely, and end the process with a deep exhalation. Then, hold the mouthpiece firmly against the lips, inhale the entire volume of the balloon in one breath, hold the breath for 10 (± 2.5) seconds, and then exhale normally. After completing the inhalation procedure, instruct the patient to lie down.

[0628] Further details regarding administration of 5-MeO-DMT by inhalation are disclosed in Example 1 of WO 2020 / 169850A1, the contents of which are incorporated herein by reference.

[0629] Example 2 - Preparation of High Purity 5-MeO-DMT

[0630] 5-MeO-DMT (2.0 g) was dissolved in MTBE (4 mL, 2.0 volumes) at 35 to 40 ° C and then cooled to room temperature within 30 minutes. After stirring at room temperature for 50 minutes, no crystallization was observed, so the batch temperature was reduced to 7 to 12 ° C within 30 minutes. Crystallization occurred after stirring at 7 to 12 ° C for 10 minutes. It was then stirred at 7 to 12 ° C for 1 hour, and the batch was subsequently filtered. After washing with MTBE (1 mL, 0.5 volumes) at 7 to 12 ° C, the batch was dried under vacuum for 3.5 hours to obtain 1.02 g of light orange solid (50% recovery). As described in WO 2020 / 169850 A1, the purity of the separated solid was analyzed by HPLC. The purity is 99.74% area.

[0631] The analytical results further indicated that the level of individual impurities was less than 0.10% area. Solvent analysis of the sample indicated MTBE level was 17 ppm.

[0632] Example 3-5-Preparation of MeO-DMT Hydrobromide

[0633] 5-MeO-DMT HBr was prepared on a 100 mg scale.

[0634] 5-MeO-DMT free base was combined with isopropyl acetate (10 vol) and the resulting 5-MeO-DMT solution was heated to 50° C. HBr (1 M in ethanol, 1 eq) was charged in a single aliquot. The mixture was maintained at this temperature and equilibrated for 3 hours.

[0635] After 1 hour, a suspension was formed. The suspension was finally cooled to room temperature and equilibrated for 18 hours. The solid was isolated by filtration and dried in vacuo at 40°C for 18 hours.

[0636] An off-white crystalline material was obtained.

[0637] The salt has a melting point of 174°C and is characterized in that it has an X-ray diffraction pattern comprising peaks at 14.5°2·±0.2°2·; 16.7°2·±0.2°2·; 17.0°2·±0.2°2·; 20.6°2·±0.2°2·; 20.7°2·±0.2°2·; 21.4°2·±0.2°2·; 24.2°2·±0.2°2·; 24.8°2·±0.2°2·; 25.3°2·±0.2°2·; 27.4°2·±0.2°2·; which is measured using Cu K· radiation.

[0638] Example 4 - Determination of Inhibition Constants of Central 5-HT1A and 5-HT2A Receptors in Postmortem Human Brain Membranes Preparations

[0639] In the present study, the affinity of three psychedelic test compounds (psilocybin dephosphate, DMT, and 5-MeO-DMT) for 5-HT1A and 5-HT2A receptors in postmortem human brain tissue (from the hippocampus and frontal cortex, respectively) was determined using radioligand binding techniques.

[0640] Human brain samples were obtained from the Edinburgh Sudden Death Brain Bank. All donors died suddenly, had no history of coma, psychiatric or neurological disease, were under 65 years old, and had a postmortem interval of less than or equal to 72 hours.

[0641] Binding to 5-HT1A receptors in postmortem human hippocampus

[0642] The hippocampus was homogenized in ice-cold 0.25M sucrose (1:30 weight / volume) using an electric Teflon pestle (grinded 12 times at 120rpm). Myelin and cell debris were removed by centrifugation at 1,000g for 10 minutes. The supernatant was stored on ice, and the precipitate was homogenized again in 0.25M sucrose (1:15 weight / volume) and centrifuged at 750g for 10 minutes. The supernatant was merged and diluted with ice-cold membrane preparation buffer (1:100 weight / volume), using a tightly fitting glass / Teflon homogenizer (12 times, 800rpm), and centrifuged at 20,500g for 10 minutes. The precipitate was resuspended in ice-cold membrane preparation buffer, incubated at 37°C for 10 minutes, and then centrifuged at 20,500g for 10 minutes. The precipitate was resuspended and centrifuged for the last time to wash the tissue (20,500xg, 10 minutes). The resulting pellet was then resuspended in ice-cold assay buffer at a tissue concentration equal to 3.125 mg tissue wet weight / ml. All centrifugations were performed at 4°C. The membrane preparation buffer consisted of 50 mM Tris-HCl, pH 7.7, 4 mM CaCl2, and 0.1% ascorbic acid. The assay buffer consisted of 50 mM Tris, pH 7.7, 4 mM CaCl2, 0.1% ascorbic acid, and 10 μM Pargyline.

[0643] For saturation binding assays, hippocampal membranes (400 μl; equivalent to 1.25 mg wet weight tissue / tube) were incubated with 50 μl of 0.075–9.6 nM [ 3 H] 8-OH-DPAT and 50 μl of assay buffer (total binding) or 50 μl of 1 μM WAY 100635 (non-specific binding) were incubated for 30 minutes at 25° C. Wash buffer consisted of 50 mM Tris, pH 7.7.

[0644] In the displacement assay, hippocampal membranes (400 μl; equivalent to 1.25 mg wet weight tissue / tube) were mixed with 50 μl of 0.6 nM [ 3 H] 8-OH-DPAT and 50 μl of assay buffer (total binding) or 50 μl of 1 μM WAY 100635 (non-specific binding) or 50 μl of one of the test compounds at one of ten concentrations between 1 and 10000 nM were incubated at 25°C for 30 min.

[0645] Membrane-bound radioactivity was recovered by vacuum filtration through Skatron 11731 filters presoaked in 0.5% polyethyleneimine (PEI) using a Skatron cell harvester. The filters were quickly washed with ice-cold wash buffer (wash settings 0,9,9) and radioactivity was determined by liquid scintillation counting (1 ml Packard MV Gold scintillation counter).

[0646] Nonlinear regression was used to calculate the compound concentration required to inhibit specific binding by 50% (IC 50 ) and the Hill slope. K was calculated using a single-site binding model that allowed for ligand depletion. i .

[0647] Binding to 5-HT2A receptors in postmortem human frontal cortex

[0648] The frontal cortex was homogenized in ice-cold 0.25M sucrose (1:30 weight / volume) using an electric Teflon pestle (12 times at 120 rpm). Myelin and cell debris were removed by centrifugation at 1,000 g for 10 minutes. The supernatant was stored on ice, and the pellet was homogenized again in 0.25M sucrose (1:15 weight / volume) and centrifuged at 750 g for 10 minutes. The supernatants were combined and diluted with ice-cold 50 mM Tris-HCl assay buffer, pH 7.4 (1:100 weight / volume), homogenized using a tightly fitting glass / Teflon homogenizer (12 times, 800 rpm), and centrifuged at 20,500 g for 10 minutes. The pellet was further centrifuged twice to wash the tissue (20,500 x g, 10 minutes). The resulting pellet was then resuspended in ice-cold 50 mM Tris-HCl assay buffer, pH 7.4, with a tissue concentration equal to 10 mg tissue wet weight / ml. All centrifugations were performed at 4°C.

[0649] For saturation binding assays, frontal cortex membranes (400 μl; equivalent to 4 mg tissue wet weight / tube) were incubated with 50 μl of 0.00625–0.8 nM [ 3 H]MDL-100,907 and 50 μl of assay buffer or 50 μl of 10 μM ketanserin (non-specific binding) were incubated for 60 minutes at 25° C. Assay and wash buffers consisted of 50 mM Tris-HCl buffer pH 7.4.

[0650] In the displacement assay, frontal cortex membranes (400 μl; equivalent to 4 mg wet weight tissue / tube) were incubated with 50 μl of 0.1 nM [3H]MDL-100,907 and either 50 μl of assay buffer (total binding) or 50 μl of 10 μM ketanserin (nonspecific binding) or 50 μl of one of ten concentrations of test compound between 1 and 10000 nM for 60 min at 25°C.

[0651] Membrane-bound radioactivity was recovered and determined as described above. Data analysis was also performed as described above.

[0652] result

[0653] Confirmed 3 The dissociation constant (K) of 8-OH-DPAT for 5-HT1A receptors in the hippocampal membrane of postmortem human brain tissue from three donors d The obtained dissociation constant (K d values) were 0.51, 0.28 and 0.52 nM, respectively.

[0654] Average inhibition constants (K) of dephosphorylated psilocybin, DMT, and 5-MeO-DMTi The Hill slopes of all compounds were close to unity, indicating a single-site binding model.

[0655] Confirmed 3 Dissociation constant (K) of MDL-100,907 for 5-HT2A receptors in the frontal cortex membranes of postmortem human brain tissue from three donors d The obtained dissociation constant (K d values) were 0.11, 0.08 and 0.08 nM respectively.

[0656] Average inhibition constants (K) of dephosphorylated psilocybin, DMT, and 5-MeO-DMT i The Hill slopes for all compounds were close to unity, indicating a single-site binding model.

[0657] The selectivity ratios of dephosphorylated psilocybin, DMT, and 5-MeO-DMT for 5-HT2A receptors over 5-HT1A receptors are 0.78, 3.1, and 68, respectively.

[0658] Example 5-5-Toxicology Testing of MeO-DMT

[0659] 5-MeO-DMT did not induce mutations in four histidine-requiring strains of Salmonella typhimurium (TA98, TA100, TA1535, and TA1537) and one tryptophan-requiring strain of Escherichia coli (WP2 uvrA pKM101). These conditions included treatment at concentrations up to 5000 μg / plate (the maximum concentration recommended according to current regulatory guidelines) in the absence and presence of a rat liver metabolic activation system (S-9).

[0660] Example 6-5-Pharmacokinetic Evaluation of MeO-DMT and Toxoplasmamine

[0661] To study the pharmacokinetic properties of 5-MeO-DMT, three groups of 8 subjects were divided. Subjects were administered a single dose of 6 mg, 12 mg, or 18 mg 5-MeO-DMT via inhalation. Blood samples were obtained at 1, 2, 4, 7, 10, 15, 20, 30, 45 minutes and 1, 1.5, 2, 3, and 4 hours after administration, respectively.

[0662] 5-MeO-DMT concentrations were determined using LC-MS / MS. PK parameters were generated by algebraic analysis of concentration versus time plots for each individual. Analysis was performed using Phoenix WinNonlin 6.3 software.

[0663] The median Cmax values ​​obtained for the three groups were 11.85 ng / ml (6 mg group), 22.90 ng / ml (12 mg group), and 38.45 ng / ml (18 mg group), respectively.

[0664] Table 1 below shows the median percentages of plasma concentration relative to Cmax determined at the indicated time points.

[0665]

[0666] Pharmacokinetic measurements were also performed for a dosing regimen that relied on up-titration, and substantially similar results were obtained.

[0667] The blood concentration of the 5-MeO-DMT metabolite bufotoxin was also determined. Only in a few samples were the concentrations above the lower limit of quantification (LLOQ) (25 pg / ml). From 15 minutes onwards, the bufotoxin concentrations were always below the LLOQ.

[0668] Essentially similar observations were made when subjects who received an up-titration regimen were included.

[0669] Example 7 - Clinical Trial in Patients Suffering from TRD

[0670] A Phase 1 / 2 clinical trial of 5-MeO-DMT administered via inhalation as described herein has been completed in patients with treatment-resistant major depressive disorder (TRD). This trial is designed in two parts. Part A is an open-label, single-arm, single-dose Phase 1 trial with two dose levels (12 mg (n=4) and 18 mg (n=4)). Part B is an open-label, single-arm Phase 2 trial with an individualized dosing regimen and a step-wise increase in the 5-MeO-DMT dose within the patient. Patients (n=8) receive at least one and up to three doses of 5-MeO-DMT (6 mg, 12 mg, and 18 mg) per day, with higher doses only being administered when the previously administered dose does not achieve a peak experience. The primary endpoint of Part A is to evaluate the safety and tolerability of a single dose of 5-MeO-DMT in TRD patients. The primary endpoint of Part B is to evaluate the effect on depression severity, as assessed by the proportion of patients who are relieved on the seventh day after administration, with relief defined as a total MADRS score of less than or equal to 10.

[0671] In Part A, 3 of 4 patients in both groups (12 mg and 18 mg) experienced at least one ADR, all of which were mild and resolved spontaneously. No SAEs were reported.

[0672] Two of four patients (50%) in the 12 mg group and one of four patients (25%) in the 18 mg group had MADRS remission on day 7 after dosing, and another patient (25%) in the 18 mg group had MADRS clinical response on day 7 after dosing. The mean MADRS change from baseline on day 7 was -21.0 (-65%) in the 12 mg group and -12.8 (-41%) in the 18 mg group.

[0673] In Part B, 7 of 8 patients (87.5%) experienced at least one ADR. All ADRs resolved spontaneously. No SAEs were reported.

[0674] At day 7, seven of eight patients (87.5%) achieved MADRS remission, achieving the primary endpoint (p<0.0001). The mean MADRS change from baseline at day 7 was 24.4 (76%).

[0675] No clinically significant changes were observed in any safety laboratory analyses, vital signs, psychiatric safety assessments, or measures of cognitive function in Part A or Part B.

[0676] The results are summarized in the table below.

[0677]

[0678] Table 2-A Scores recorded for relevant MADRS and BPRS items for patients assigned to intra-day individualized dosing regimen (IDR). Item scores represent the sum of individual patient scores for all patients in the IDR group (n=8). Assessment 2 hours (MADRS) or 3 hours (BPRS) after administration of the last dose.

[0679]

[0680]

[0681] Table 2-B Scores recorded for relevant MADRS and BPRS items for patients assigned to intra-day individualized dosing (IDR). Item scores represent the sum of individual patient scores for all patients in the IDR group (n=8). Assessment on Day 1.

[0682] Scale items Scale Baseline IDR Day 7 Improvement on Day 7 Percent Improvement Reduced sleep MADRS 25 9 16 64.00% Difficulty concentrating MADRS 30 9 21 70.00% Laziness MADRS 27 3 24 88.89% Loss of sensation MADRS 36 6 30 83.33% Inner tension MADRS 26 12 14 53.85% Pessimistic thoughts MADRS 28 3 25 89.29% Suicidal thoughts MADRS 11 3 8 72.73% Guilt BPRS 34 10 24 70.59% nervous BPRS 16 10 6 37.50% anxiety BPRS 37 17 20 54.05% Emotional withdrawal BPRS 13 8 5 38.46% Emotional blunting BPRS 15 8 7 46.67%

[0683] Table 2-C Scores recorded for relevant MADRS and BPRS items for patients assigned to intra-day individualized dosing (IDR). Item scores represent the sum of individual patient scores for all patients (n=8) in the IDR group. Assessment on Day 7.

[0684] Scale items Scale Baseline 12 mg 2 / 3 hours Improvement after 2 / 3 hours Percent Improvement Difficulty concentrating MADRS 16 7 9 56.25% Laziness MADRS 16 10 6 37.50% Loss of sensation MADRS 16 9 7 43.75% Inner tension MADRS 13 2 11 84.62% Pessimistic thoughts MADRS 16 8 8 50.00% Suicidal thoughts MADRS 8 3 5 62.50% Guilt BPRS 18 9 9 50.00% nervous BPRS 14 9 5 35.71% anxiety BPRS 25 11 14 56.00% Emotional withdrawal BPRS 13 11 2 15.38% Emotional blunting BPRS 11 8 3 27.27%

[0685] Table 3-A Scores recorded for relevant MADRS and BPRS items for patients assigned to the 12 mg dosing regimen. Item scores represent the sum of individual patient scores for all patients (n=4) in the 12 mg group. Assessment 2 hours (MADRS) or 3 hours (BPRS) after dose administration.

[0686] Scale items Scale Baseline 12 mg Day 1 Improvement on Day 1 Percent Improvement Reduced sleep MADRS 12 10 2 16.67% Difficulty concentrating MADRS 16 2 14 87.50% Laziness MADRS 16 0 16 100.00% Loss of sensation MADRS 16 1 15 93.75% Inner tension MADRS 13 3 10 76.92% Pessimistic thoughts MADRS 16 7 9 56.25% Suicidal thoughts MADRS 8 5 3 37.50% Guilt BPRS 18 5 13 72.22% nervous BPRS 14 6 8 57.14% anxiety BPRS 25 6 19 76.00% Emotional withdrawal BPRS 13 8 5 38.46% Emotional blunting BPRS 11 6 5 45.45%

[0687] Table 3-B Scores recorded for relevant MADRS and BPRS items for patients assigned to the 12 mg dosing regimen. Item scores represent the sum of individual patient scores for all patients (n=4) in the 12 mg group. Assessment on Day 1.

[0688] Scale items Scale Baseline 12 mg Day 7 Improvement on Day 7 Percent Improvement Reduced sleep MADRS 12 6 6 50.00% Difficulty concentrating MADRS 16 3 13 81.25% Laziness MADRS 16 3 13 81.25% Loss of sensation MADRS 16 1 15 93.75% Inner tension MADRS 13 5 8 61.54% Pessimistic thoughts MADRS 16 8 8 50.00% Suicidal thoughts MADRS 8 7 1 12.50% Guilt BPRS 18 5 13 72.22% nervous BPRS 14 6 8 57.14% anxiety BPRS 25 6 19 76.00% Emotional withdrawal BPRS 13 6 7 53.85% Emotional blunting BPRS 11 5 6 54.55%

[0689] Table 3-C Scores recorded for relevant MADRS and BPRS items for patients assigned to the 12 mg dosing regimen. Item scores represent the sum of individual patient scores for all patients (n=4) in the 12 mg group. Assessment on Day 7.

[0690] Example 8 - Clinical Trial of Administering 5-MeO-DMT to Patients with Postpartum Depression via Inhalation

[0691] This single-arm, open-label clinical trial will involve 15 adult female patients clinically diagnosed with postpartum depression (PPD).

[0692] Patients received a single-day individualized 5-MeO-DMT dosing regimen via vaporized inhalation.

[0693] More specifically, patients will receive up to three doses of 5-MeO-DMT on Day 0: 6 mg, 12 mg, and 18 mg.

[0694] 1. All patients will receive an initial dose of 6 mg 5-MeO-DMT.

[0695] 2. The second dose (12 mg) will be administered only in the following cases:

[0696] a. Peak experience (total score ≥ 75) not achieved after 6 mg dose, and

[0697] b. According to the researchers, the 6 mg dose was safe and well tolerated.

[0698] c. Any psychoactive effects (PsE) from the previous dose have resolved, and

[0699] d. Pre-dose vital signs and forced expiratory volume in one second (FEV1) were within normal ranges, or if outside the normal range, were of no clinical significance according to the investigator.

[0700] 3. Similarly, the third dose (18 mg) will only be administered if:

[0701] a. Peak experience not achieved after 12 mg dose (total score ≥ 75), and

[0702] b. According to the researchers, the 12 mg dose was safe and well tolerated, and

[0703] c. Any PsE from the previous dose has resolved, and

[0704] d. Pre-dose vital signs and forced expiratory volume in one second (FEV1) were within normal ranges, or if outside the normal range, were of no clinical significance according to the investigator.

[0705] Patients will be assessed for peak psychedelic experience (based on a patient-rated visual analog scale, or PE scale), sedation, and other endpoints after dosing. Follow-up visits are planned on days 1 and 7 after dosing.

[0706] All patients considered for participation in a clinical trial must meet the following criteria:

[0707] 1. Be female and be between 18 and 45 years old (inclusive) at the time of screening.

[0708] 2. Body mass index (BMI) at screening is between 18.5 and 35 kg / m 2 is within the range of (including the end value).

[0709] 3. Meet the trial criteria for PPD as assessed by a trial psychiatrist or registered psychologist:

[0710] a. A diagnosis of major depressive disorder without psychotic features confirmed by the Mini-International Neuropsychiatric Interview (MINI), with perinatal onset no earlier than pregnancy and no later than the first 4 weeks postpartum.

[0711] b. Montgomery-Asberg Depression Rating Scale (MADRS) total score equal to or greater than 28 at screening and on Day 0 before dosing.

[0712] 6. Patients must stop breastfeeding at the time of screening; or if they are still breastfeeding or actively breastfeeding at the time of screening, they must agree to temporarily stop breastfeeding from before receiving the study drug on Day 0 to 24 hours after the last dose, and express and discard all breast milk within these 24 hours as needed, but they need to express / discard breast milk 2.5 hours after the last dose and 24 hours after the last dose before they can resume breastfeeding.

[0713] 4. Must agree to complete abstinence (complete avoidance of heterosexual intercourse) or use highly effective (failure rate <1%), medically approved contraceptive methods for 30 days before administration and 90 days after 5-MeO-DMT administration. Patients must have negative pregnancy test results at screening and the day before the test (Day -1).

[0714] 5. Willing to postpone the start of other antidepressant or antianxiety medications until after the end of the trial on Day 7, and agree to keep any psychological therapy unchanged during the trial.

[0715] Potential patients who meet any of the following key exclusion criteria will be excluded from this trial:

[0716] 1. Based on medical history, psychiatric assessment and MINI evaluation, currently or previously diagnosed with bipolar disorder, manic or hypomanic episodes, psychotic disorders, major depressive disorder (MDD) or other mood disorders with psychotic features, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), autism spectrum disorder, borderline personality disorder, schizophrenia, delusional disorder, paranoid personality disorder, schizoaffective disorder, clinically significant intellectual disability, or any other psychiatric comorbidity that, in the investigator's judgment, makes the patient unsuitable for the trial.

[0717] 2. One or more first- or second-degree relatives currently or previously diagnosed with bipolar disorder, psychotic disorder, or other mood disorder with psychotic features (including MDD).

[0718] 3. The patient is at significant risk of suicide based on medical history, psychiatric evaluation, and assessment of suicidal ideation and behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS), as judged by the trial psychiatrist or registered psychologist.

[0719] 4. Taking antidepressants within 14 days or 5 half-lives (whichever is longer) before administration (exception: in the case of fluoxetine, within the past 5 weeks).

[0720] 5. Any other drug with monoamine oxidase inhibitor (MAOI) activity has been taken within 14 days or 5 half-lives (whichever is longer) before administration.

[0721] 6. Previous serious adverse reactions to hallucinogenic or psychedelic drugs (e.g., psilocybin, Psilocybe spp. mushrooms, 5-MeO-DMT, DMT, ayahuasca, LSD, mescaline) based on the investigator's judgment.

[0722] 7. Known allergy or hypersensitivity to 5-MeO-DMT or any other contraindications.

[0723] 8. Any current or past clinically significant illness that, in the investigator's judgment, makes the patient unsuitable for participation in the trial (e.g., severe infection, lung disease, uncontrolled hypertension, new-onset gestational hypertension disorder during pregnancy or postpartum (e.g., gestational hypertension, preeclampsia-eclampsia, superimposed preeclampsia), uncontrolled diabetes, severe cardiovascular disease, severe liver or kidney failure, severe brain disorder (including epilepsy, stroke, dementia, degenerative nervous system disease, meningitis, encephalitis, and head injury with loss of consciousness).

[0724] 9. Taking any medication or other substance that, in the judgment of the researcher, makes the patient unsuitable for participating in the trial.

[0725] 10. Clinically significant abnormalities in physical examination, vital signs, ECG, or clinical laboratory parameters that render the patient unsuitable for the trial, based on the investigator's judgment.

[0726] 11. Patient has a positive pregnancy test at Screening or the day before testing (Day -1), is pregnant, or plans to become pregnant during the course of the trial and up to 90 days after 5-MeO-DMT administration.

[0727] 12. The patient has a DSM-5 drug or alcohol use disorder within 6 months prior to screening.

[0728] The primary objective of the trial was to determine the onset and 7-day durability of the antidepressant effect of a single-day individualized dosing regimen (6 mg, 12 mg, and 18 mg 5-MeO-DMT) in adult female patients with PPD.

[0729] Secondary objectives were to determine the antidepressant effects, anxiolytic effects, effects on maternal behavior, safety and tolerability, intensity and duration of psychoactive effects (PsE) of a single-day individualized dosing regimen (6 mg, 12 mg, and 18 mg 5-MeO-DMT) in adult women with PPD; and effects on cognitive outcomes.

[0730] The exploratory objective was to determine the amounts of 5-MeO-DMT and metabolites, bufotoxin, and 5-methoxyindole-3-acetic acid (5-MIAA) in breast milk, blood, and urine (metabolite identification screening could be performed as needed) following single-day administration of a single individualized IDR (6 mg, 12 mg, and 18 mg 5-MeO-DMT) to adult female PPD patients as measured by LC / MS / MS.

[0731] The primary endpoint of this study was to evaluate the antidepressant effect of 5-MeO-DMT as assessed by the change from baseline in the MADRS at day 7.

[0732] Secondary endpoints included evaluation of the antidepressant effects of 5-MeO-DMT by:

[0733] The antidepressant effects of 5-MeO-DMT were evaluated by:

[0734] ○ Proportion of patients in remission (MADRS ≤ 10) 2 hours after the final dose of study drug on Day 0, Day 1, and Day 7;

[0735] ○ Change from baseline in MADRS assessed 2 hours after the final study drug dose on Day 0 and on Day 1;

[0736] ○ Proportion of responders (reduction in MADRS total score ≥50% from baseline) 2 hours after the final study drug dose on Day 0, Day 1, and Day 7;

[0737] ○ Change from baseline in Clinical Global Impression-Severity (CGI-S) 2 hours after the final study drug dose on Day 0, Day 1, and Day 7;

[0738] ●Effects on maternal behavior, as assessed by change from baseline to day 7 in the Barkin Index of Maternal Functioning (BIMF) total and subscale scores;

[0739] Exposure to 5-MeO-DMT and bufotoxin in breast milk obtained on the day before testing (Day -1), 1 hour after the last dose of study drug, at discharge, on the evening of Day 0, and on Days 1 and 7;

[0740] 5-MeO-DMT and bufotoxin exposure in blood obtained one day before testing (Day -1), 1 hour after the last dose of study drug, at discharge, and on Days 1 and 7;

[0741] The safety and tolerability of 5-MeO-DMT were evaluated by:

[0742] ○ Report treatment-emergent adverse events (TEAEs);

[0743] ○ Clinically significant changes from baseline in ECG, vital signs, safety laboratory assessments, and peak flow spirometry;

[0744] ○ Sedation assessment (Modified Observer Assessment of Alertness and Sedation [MOAA / S]) was performed after each dose (when PsE resolved and 60 minutes after each study drug dose) and as part of the discharge evaluation on Day 0;

[0745] ○ Change from baseline in the Clinically Administered Dissociative State Scale (CADSS) assessed as part of the discharge evaluation on Days 0, 1, and 7;

[0746] ○ Change from baseline in the Brief Psychiatric Rating Scale (BPRS) assessed as part of the discharge evaluation on Days 0, 1, and 7;

[0747] ○ Change from baseline in the C-SSRS assessed as part of the discharge evaluation on Day 0, Day 1, and Day 7;

[0748] ○ Change from baseline in the YMRS assessed as part of the discharge evaluation on Day 0, Day 1, and Day 7;

[0749] ● Patient-experienced PsE reported 30 to 60 minutes after each dose, at which time PsE had resolved:

[0750] ○ PsE assessment using the Peak Experience (PE) scale to assess the achievement of PE (PE scale total score ≥ 75);

[0751] ○ Challenging Experience Questionnaire (CEQ);

[0752] ○Mystical Experience Questionnaire (MEQ-30);

[0753] Duration of PsE was defined as the time from study drug administration to when PsE had resolved (investigator-rated and patient-rated), which was completed within 30 to 60 minutes after each dose.

[0754] Currently, one patient diagnosed with postpartum depression by a psychiatrist has been recruited to participate in the clinical trial. The diagnosis of major depressive disorder without psychotic features was confirmed by the Mini-International Neuropsychiatric Interview (MINI) (v7.0.2) with perinatal onset no earlier than during pregnancy and no later than the first 4 weeks postpartum. The patient was diagnosed with postpartum depression after the birth of her third child. The patient completed all scheduled clinic days. The inhalation procedure was adequately performed by the patient and well tolerated, with no adverse events related to the inhalation.

[0755] result

[0756] No other noteworthy changes in vital parameters occurred, except for a transient, clinically insignificant increase in heart rate and blood pressure shortly after 5-MeO-DMT administration. ECG (3 hours after administration) and safety laboratory analysis (7 days), CADSS (3 hours, 1 day, and 7 days) were unremarkable. The few adverse events reported (left abdominal cramping pain and headache, both on day 0) were mild, transient, and resolved spontaneously by the end of the study.

[0757] Regarding the intensity of the psychedelic experience, the PES score achieved upon exposure to the nominal dose of 6 mg was recorded to be 17.3. This score indicated that a subsequent higher dose of 12 mg would need to be continued as per the design of the individualized dosing regimen. The PES score achieved at this dose was 85.7 and ≥75, indicating that the patient had a peak psychedelic experience and completed the IDR.

[0758] It is noteworthy that patients reported significant improvements in their depressive symptoms, as assessed by MADRS at the earliest assessment time point (2 hours) after drug administration, and the effect was maintained over time (Table 4). Patients also met the criteria for MADRS response (at least 50% improvement compared to baseline) and MADRS remission (MADRS total score equal to or less than 10).

[0759] Table 4-MADRS / BPRS scoring table

[0760]

[0761]

[0762] Significant improvements were noted in several MADRS items in particular. The individual items are summarized in Table 4. Patients' baseline scores for some items reflected the absence of symptoms (loss of appetite, difficulty concentrating, suicidal thoughts), while scores for items reflecting severe symptoms (e.g., decreased sleep, inner tension) improved significantly.

[0763] Likewise, several BPRS items improved, including somatic problems, anxiety, emotional withdrawal, guilt, and tension.

[0764] Furthermore, as summarized in Table 5, improvements in maternal function were demonstrated by the improvement in BIMF scores recorded on day 7, with the total score increasing from 92 to 105, an improvement of 14% (total score can reach 120).

[0765] Several domains of maternal functioning as defined by Barkin et al were also assessed. Table 6 summarizes the improvements in each domain of functioning in more detail.

[0766] Here, significant improvements in self-care, mental health and management were achieved, with % improvements ranging from 18% (management) to (44%) % (self-care). These improvements reinforced the relationship between improvements in depression items, as assessed by MADRS and improvements in maternal functioning.

[0767] It is important to note that the patient's scores were relatively high before treatment. In some areas of functioning, the scores were at or near the maximum (see Table 6), which limited the scope for improvement with therapy.

[0768] Table 5-BIMF score table

[0769]

[0770] Table 6-BIMF functional area scoring table

[0771]

[0772]

[0773] Summary and Conclusion

[0774] A. An individualized dosing regimen of 6 mg 5-MeO-DMT followed by 12 mg 5-MeO-DMT via inhalation was well tolerated and induced a surprising and highly significant clinical response in patients formally diagnosed with postpartum depression.

[0775] B. Rapid clinical response within 2 hours after 5-MeO-DMT administration. This rapid onset of action is not common and has not been seen in traditional antidepressant classes, including tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), etc., which usually take 4 to 6 weeks to show effects.

[0776] C. According to the IDR, the patient experienced clinical remission within 2 hours of 5-MeO-DMT administration. This is superior to any approved treatment for postpartum depression as well as all previously tested psychedelics.

[0777] D. Although 5-MeO-DMT was only administered once and is no longer effectively present in the body within this time frame (see pharmacokinetic data in Example 6 above), a significant clinical response persisted over the 7-day follow-up period. This observation supports the superior clinical profile of 5-MeO-DMT and allows for convenient dosing intervals.

[0778] E. In addition to the antidepressant effects, endpoints assessing other symptoms (such as somatic problems, emotional withdrawal, anxiety, guilt, and tension) were also positively affected, supporting the use of 5-MeO-DMT in patients with other psychiatric disorders.

[0779] F. In addition to the antidepressant effects, endpoints assessing maternal functioning such as self-care, psychological well-being, and management assessed using the BIMF were also positively affected, supporting the idea that 5-MeO-DMT has additional benefits beyond improving core depressive symptoms in patients with PPD.

[0780] The salient aspects demonstrate that, when used in accordance with the present invention, 5-MeO-DMT has significantly improved efficacy compared to approved pharmacotherapy for postpartum depression and all previously tested psychedelics.

[0781] Combined with the short duration of the acute psychedelic effect and the favorable safety profile, these data suggest that the present invention solves the technical problem of providing improved psychoactive therapies for patients with postpartum depression.

[0782] Example 9 - Clinical Trial of Administering 5-MeO-DMT to Bipolar II Patients via Inhalation

[0783] This single-arm, open-label clinical trial will involve 15 adult patients with bipolar II disorder who are currently experiencing a major depressive episode.

[0784] Patients currently taking antidepressant medications need to stop taking them or taper off the medication over time.

[0785] Patients received a single-day individualized 5-MeO-DMT dosing regimen via vaporized inhalation.

[0786] More specifically, patients will receive up to three doses of 5-MeO-DMT on the administration day (Day 0): 6 mg, 12 mg, and 18 mg.

[0787] 1. All patients will receive an initial dose of 6 mg 5-MeO-DMT.

[0788] 2. The second dose (12 mg) will be administered only in the following cases:

[0789] a. Peak experience not achieved after 6 mg dose (PES total score ≥ 75), and

[0790] b. The 6 mg dose was safe and well tolerated.

[0791] 3. Similarly, the third dose (18 mg) will only be administered if:

[0792] a. Peak experience not achieved after 12 mg dose (PES total score ≥ 75), and

[0793] b. The 12 mg dose was safe and well tolerated.

[0794] The patients’ peak psychedelic experience will be assessed based on the patient-rated PES described above, sedation after dosing, and other endpoints. Follow-up visits are planned on days 1 and 7 after dosing.

[0795] Patient selection was based on the following key inclusion criteria:

[0796] 1. Understand the nature of the clinical trial and provide signed and dated written informed consent in accordance with local regulations before any trial-related procedures are carried out.

[0797] 2. Male or female, aged between 18 and 64 years old (inclusive) at the time of screening.

[0798] 3. Meets trial criteria for bipolar disorder type II and is experiencing a major depressive episode as assessed by the trial psychiatrist or registered clinical psychologist:

[0799] a. Meet the diagnostic criteria for bipolar II disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and be confirmed to be currently suffering from a major depressive episode by the Mini-International Neuropsychiatric Interview (MINI);

[0800] b. Montgomery-Asberg Depression Rating Scale (MADRS) total score equal to or greater than 24 at screening and before the first dose on Day 0;

[0801] 4. The total score of the Young's Mania Rating Scale (YMRS) is less than or equal to 8 at screening and before the first dose on day 0;

[0802] 5. Agree to keep any psychotherapy unchanged and not start any new psychoactive medications during the trial.

[0803] 6. Female patients must be surgically sterilized (hysterectomy, tubal ligation, or bilateral oophorectomy (6 months before screening)), or be postmenopausal and have achieved amenorrhea or complete abstinence (complete avoidance of heterosexual intercourse) in the past 2 years, or use a medically approved highly effective (failure rate <1%) contraceptive method 30 days before and 90 days after 5-MeO-DMT administration, including but not limited to bilateral tubal ligation / blockage, hormonal contraceptives that suppress ovulation, intrauterine devices (including hormone-releasing intrauterine devices / systems), and must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day before the test (day -1).

[0804] 7. Male patients must use preventive contraception (i.e., use of condoms containing spermicide or abstinence) and must not donate sperm within 30 days of 5-MeO-DMT administration.

[0805] Potential patients who meet any of the following key exclusion criteria will be excluded from this trial:

[0806] 1. Based on medical history, psychiatric assessment and MINI evaluation, currently or previously diagnosed with bipolar disorder type I, manic episode, psychotic disorder, major depressive disorder (MDD) or other mood disorders with psychotic features, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), autism spectrum disorder, borderline personality disorder, schizophrenia, delusional disorder, paranoid personality disorder, schizoaffective disorder, clinically significant intellectual disability, or any other psychiatric comorbidity that, in the investigator's judgment, makes the patient unsuitable for the trial.

[0807] 2. One or more first- or second-degree relatives currently or previously diagnosed with a psychotic disorder, bipolar disorder type I, or MDD with psychotic features.

[0808] 3. Significant suicide risk, defined as: (a) suicidal ideation as described in C-SSRS Item 4 or 5 within the past year, during the screening period, or at baseline; or (b) suicidal behavior within the past year; or (c) clinical assessment of significant suicide risk during the clinical interview; or (d) non-suicidal self-injurious behavior within the past year.

[0809] 4. Taking antidepressants within 7 days or 5 half-lives (whichever is longer) before administration (exception: in the case of fluoxetine, within the past 5 weeks).

[0810] 5. Taking drugs with monoamine oxidase inhibitor (MAOI) activity within 14 days or 5 half-lives (whichever is longer) before administration.

[0811] 6. Received mood stabilizer therapy (e.g., lamotrigine, valproate, atypical antipsychotics) within 14 days (28 days for lithium) or 5 half-lives (whichever is longer) prior to dosing, or received mood stabilizer therapy at screening, or is expected to require mood stabilizer therapy during the study (based on the investigator's judgment).

[0812] 7. Previous serious adverse reactions to hallucinogens or psychedelic drugs, as determined by the investigator.

[0813] 8. Known allergy or hypersensitivity to 5-MeO-DMT or any other contraindications.

[0814] 9. Current or past clinically significant illness (e.g., severe infection, severe lung disease, uncontrolled hypertension, uncontrolled diabetes, severe cardiovascular disease, severe liver or kidney failure, severe brain disorder (including epilepsy, stroke, dementia, degenerative nervous system disease, meningitis, encephalitis, and head injury with loss of consciousness) that may interfere with the interpretation of the trial results, pose a risk to the patient's health, or make the patient unsuitable for participation in the trial according to the investigator's judgment.

[0815] 10. Taking any medication or other substance that, in the judgment of the researcher, makes the patient unsuitable for participating in the trial.

[0816] 11. Clinically significant abnormalities in physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory parameters that render the patient unsuitable for the trial, based on the investigator's judgment.

[0817] 12. Female patients with a positive pregnancy test at screening or the day before testing (Day -1), are pregnant or breastfeeding, or plan to become pregnant during the course of the trial and up to 30 days after 5-MeO-DMT administration.

[0818] 13. Patients with DSM-5, alcohol or substance use disorder (excluding tobacco or caffeine use disorder) within 6 months prior to screening.

[0819] The primary objective of the trial was to determine the onset and duration of antidepressant effects of a single-day individualized dosing regimen (6 mg, 12 mg, and 18 mg 5-MeO-DMT) in patients with bipolar II disorder and a current major depressive episode. Secondary objectives were to determine the effects of a single-day individualized dosing regi...

Claims

1. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating patients suffering from psychomotor retardation.

2. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 1, wherein said treatment reduces or eliminates psychomotor retardation.

3. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 2, wherein said reduction or elimination of psychomotor retardation is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, such as about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

4. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 2, wherein said reduction or elimination of psychomotor retardation occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and wherein said reduction or elimination of psychomotor retardation lasts until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

5. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from a psychiatric or neurological disorder associated with the psychomotor retardation.

6. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 5, wherein the patient suffering from a psychiatric or neurological disorder suffers from a treatment-resistant form of the disorder.

7. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from a disorder characterized by depressive episodes associated with the psychomotor retardation.

8. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 7, wherein the patient suffering from a disorder characterized by a depressive episode suffers from a treatment-resistant form of the disorder.

9. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from major depressive disorder (MDD) associated with the psychomotor retardation.

10. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 9, wherein the patient suffering from MDD suffers from a treatment-resistant form of the disorder.

11. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from postpartum depression (PPD) associated with the psychomotor retardation.

12. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 11, wherein the patient suffering from PPD suffers from a treatment-resistant form of the disorder.

13. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 11 or 12, wherein the patient also suffers from impaired maternal function.

14. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 13, wherein the patient has a Barkin Index of Maternal Functioning (BIMF) score of 80 or less, such as 65 or less.

15. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 13 or 14, wherein said treatment improves maternal function.

16. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 15, wherein said improvement in maternal function is reflected in an improvement in the BIMF total score of 10% or more, preferably 20% or more.

17. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 15 or 16, wherein said improvement in maternal function is reflected at least in an improvement in the BIMF total score at day 7; day 14; and / or day 28 after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof.

18. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 15 or 16, wherein said improvement in maternal function occurs no later than about 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in an improvement in the BIMF total score, and wherein said improvement in maternal function persists until at least 14 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in an improvement in the BIMF total score.

19. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from bipolar disorder associated with the psychomotor retardation.

20. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 19, wherein the patient suffers from bipolar II disorder associated with the psychomotor retardation.

21. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 19, wherein the patient suffers from bipolar disorder type I associated with the psychomotor retardation.

22. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 19 to 21, wherein the patient suffers from a current major depressive episode.

23. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 19 to 22, wherein the patient suffering from bipolar disorder suffers from a treatment-resistant form of the disorder.

24. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from seasonal affective disorder associated with the psychomotor retardation.

25. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 24, wherein the patient suffering from seasonal affective disorder suffers from a treatment-resistant form of the disorder.

26. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from persistent depressive disorder associated with the psychomotor retardation.

27. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 26, wherein the patient suffering from persistent depressive disorder suffers from a treatment-resistant form of the disorder.

28. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from mental and behavioral disorders associated with the psychomotor retardation due to the use of psychoactive substances.

29. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claim 28, wherein the patient suffers from a substance use disorder (SUD) associated with the psychomotor retardation.

30. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 28 or 29, wherein the patient suffers from a treatment-resistant form of the disorder.

31. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from a psychotic disorder associated with the psychomotor retardation.

32. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 31, wherein the patient suffering from a psychotic disorder suffers from a treatment-resistant form of the disorder.

33. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 4, wherein the patient suffers from schizophrenia associated with said psychomotor retardation.

34. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 33, wherein the patient suffering from schizophrenia suffers from a treatment-resistant form of the disorder.

35. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from dementia associated with the psychomotor retardation.

36. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 4, wherein the patient suffers from Alzheimer's disease dementia associated with the psychomotor retardation.

37. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 4, wherein the patient suffers from dementia with Lewy bodies associated with the psychomotor retardation.

38. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 4, wherein the patient suffers from vascular dementia associated with the psychomotor retardation.

39. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 4, wherein the patient suffers from Parkinson's disease dementia associated with the psychomotor retardation.

40. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use according to claims 1 to 4, wherein the patient suffers from Parkinson's disease associated with the psychomotor retardation.

41. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 4, wherein the patient suffers from chronic fatigue syndrome associated with the psychomotor retardation.

42. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 41, wherein the patient suffering from chronic fatigue syndrome suffers from a treatment-resistant form of the disorder.

43. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 5 to 42, wherein said treatment results in improvement of said diagnosed disorder in a patient who also suffers from associated psychomotor retardation.

44. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 43, wherein the improvement of the diagnosed disorder in patients who also suffer from associated psychomotor retardation, as reflected by a decrease in the Clinical Global Impression - Severity (CGI-S) score, is observed at about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 1 day, such as about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; at 7 days; at 14 days; and / or at 28 days.

45. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 43, wherein said improvement in said diagnosed disorder in a patient also suffering from associated psychomotor retardation occurs no later than about 2 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in a decrease in the Clinical Global Impression - Severity (CGI-S) score, and wherein said improvement in said diagnosed disorder in a patient also suffering from associated psychomotor retardation persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in a decrease in the Clinical Global Impression - Severity (CGI-S) score.

46. ​​5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 4, wherein the patient suffers from sleep disturbance associated with the psychomotor retardation.

47. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 46, wherein the sleep disorder is insomnia associated with the psychomotor retardation.

48. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 46 or 47, wherein the patient suffers from idiopathic sleep disorder associated with the psychomotor retardation.

49. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 46 to 48, wherein the patient suffers from a treatment-resistant form of the disorder.

50. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 46, 47 or 49, wherein the sleep disturbance occurs in a patient suffering from associated psychomotor retardation and also suffering from a psychiatric or neurological disorder, such as a disorder characterized by depressive episodes, for example, major depressive disorder (MDD); bipolar disorder (BD), such as bipolar disorder type I and bipolar disorder type II; postpartum depression (PPD); seasonal affective disorder and persistent depressive disorder; mental and behavioral disorders due to the use of psychoactive substances, such as substance use disorder (SUD); psychotic disorders, such as schizophrenia; dementia, such as Alzheimer's disease dementia (AD); dementia with Lewy bodies (DLB); vascular dementia and Parkinson's disease dementia; Parkinson's disease (PD); and chronic fatigue syndrome.

51. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 50, wherein said treatment results in improvement of psychomotor retardation and sleep disturbances, and further results in improvement of said related psychiatric or neurological disorders.

52. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 46 to 51, wherein said treatment results in an improvement in said sleep disorder.

53. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 52, wherein the improvement in sleep disturbance is observed on the 1st day, e.g., about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; on the 7th day; on the 14th day; and / or on the 28th day after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, as reflected by a decrease in the Clinical Global Impression-Severity (CGI-S) score.

54. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 52, wherein said improvement in said sleep disturbance occurs no later than about 24 hours after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in a decrease in the Clinical Global Impression-Severity (CGI-S) score, and wherein said improvement in said sleep disturbance persists until at least 6 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof; in particular until at least 14 days; more preferably until at least 28 days after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, said improvement being reflected in a decrease in the Clinical Global Impression-Severity (CGI-S) score.

55. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 52, wherein said improvement in said sleep disturbance, as reflected by a decrease in the Clinical Global Impression-Severity (CGI-S) score, is observed on the 7th day after the last administration of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and preferably lasts until at least 14 days, more preferably until at least 28 days.

56. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 55, wherein the 5-MeO-DMT or a salt thereof is administered at a dose or dosage regimen that causes the patient to experience a peak psychedelic experience.

57. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 56, wherein a dosage of about 4 mg to about 20 mg of 5-MeO-DMT is administered, or wherein an equimolar amount of said pharmaceutically acceptable salt is administered in place of 5-MeO-DMT.

58. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 56, wherein a dose of about 6 mg; or about 12 mg; or about 18 mg is administered, or wherein an equimolar amount of said pharmaceutically acceptable salt is administered in place of 5-MeO-DMT.

59. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 57, wherein the 5-MeO-DMT or a salt thereof is administered in a first dose in a first administration; and the 5-MeO-DMT or a salt thereof is administered in zero to six subsequent administrations; in, Unless the patient is experiencing a peak psychedelic experience, each subsequent administration uses a higher dose than the previous one.

60. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 1 to 59, wherein the 5-MeO-DMT is administered at a dose of about 2 mg to about 8 mg for a first administration, then increased to a dose of about 8 mg to about 14 mg for a second administration unless the patient has experienced a peak psychedelic experience, then increased to a dose of about 14 mg to about 20 mg for a third administration unless the patient has experienced a peak psychedelic experience, or wherein an equimolar amount of the pharmaceutically acceptable salt is administered in place of the 5-MeO-DMT.

61. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claim 60, wherein the first dose of 5-MeO-DMT is about 6 mg, the second dose of 5-MeO-DMT is about 12 mg, and the third dose of 5-MeO-DMT is about 18 mg; or wherein an equimolar amount of the pharmaceutically acceptable salt is administered instead of 5-MeO-DMT.

62. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 59 to 61, wherein the interval between two administrations is not less than 1 hour and not more than 24 hours, such as about 1 to 4 hours, preferably 1 to 2 hours.

63. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as described in claims 56 to 62, wherein the occurrence of the peak psychedelic experience is identified by achieving at least 60% of the maximum possible score in each of the four subscales (mystical, positive emotions, transcendence of time and space, and ineffable) of the 30-item Revised Mystical Experience Questionnaire (MEQ30), or by achieving at least 60% of the maximum possible score on the Ocean-like Boundlessness (OBN) dimension of the Altered States of Consciousness (ASC) Questionnaire, or by achieving a Peak Experience Scale (PES) total score of at least 75.

64. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 63, wherein the occurrence of the peak psychedelic experience is identified by achieving a Peak Experience Scale (PES) total score of at least 75.

65. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 1 to 64, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via inhalation, or by nasal, buccal or sublingual administration.

66. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 65, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered in the form of an aerosol comprising (a) a pharmaceutically acceptable gas; (b) aerosol particles of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof, wherein the aerosol has an aerosol particle mass density of about 0.5 mg / l to about 18 mg / l, such as to about 12.5 mg / l.

67. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claim 66, wherein the aerosol is generated by: a) exposing a thin layer of 5-MeO-DMT or a pharmaceutically acceptable salt thereof disposed on a solid support to thermal energy, and b) passing air through the thin layer to produce aerosol particles.

68. 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use as claimed in claims 65 to 67, wherein the dose of 5-MeO-DMT or a pharmaceutically acceptable salt thereof to be administered to the patient is inhaled via a single breath.

69. 5-MeO-DMT for use as claimed in claims 65 to 68, wherein the 5-MeO-DMT is used in the form of a free base.